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Abstract
Ovarian cancer (OC) has the highest mortality among gynecological cancers. The high
mortality is associated with the lack of an accurate screening tool to detect disease in early stage.
As a result the majority of OCs are diagnosed in late stage. Further, the molecular events
responsible for malignant transformation in the ovary remain poorly understood. Consequently,
delineating key molecular players driving OC could help elucidate potential diagnostic,
prognostic and therapeutic targets.
Receptor for hyaluronan-mediated motility (RHAMM) belongs to a group of
hyaladherins, which share a common ability to bind to hyaluronan (HA). Intracellularly,
RHAMM is involved in microtubule spindle assembly contributing to cell cycle progression. On
the cell surface, loosely tethered RHAMM forms a complex with cluster differentiation 44 and
HA to activate cell signaling pathways that promote cellular migration, invasion and
proliferation. Since RHAMM is overexpressed in a number of cancer types and it is often
associated with an aggressive cancer phenotype, I sought to determine if RHAMM similarly
contributes to OC.
I found that RHAMM is overexpressed in clinical specimens of OC by immunohistochemistry and although both primary and metastatic OCs stain equally for RHAMM,
RHAMM staining was most intense among clinically aggressive OC histologic subtypes.
Further, using an in vitro model system, I was able to show that OC cells express and secrete
RHAMM. Abrogation of RHAMM using silencing RNA technology inhibited OC cell migration
xi

and invasion suggesting that RHAMM may contribute, at least in part, to the metastatic
propensity of OC.
Since RHAMM lacks an export signal peptide sequence and has not been reported to
employ alternate mechanisms for extracellular secretion, I utilized computational analyses to
predict post-translational glycosylation events as a novel mode for RHAMM secretion. Nglycosylation inhibitors abrogated RHAMM secretion by OC cells in vitro validating my
prediction and identify a novel and potentially unconventional mode for RHAMM secretion.
Lastly, since RHAMM is secreted by OC cells, I sought to determine whether RHAMM
could be detected in bodily fluids. In a pilot study, I found that urinary levels of RHAMM are
elevated in OC patients as measured by enzyme-linked immunosorbant assays. Decreased
urinary RHAMM levels noted following cytoreductive surgery support OC as the source of
elevated urinary RHAMM levels. Finally, while obesity was associated with high urinary
RHAMM levels in OC patients, combined measurements of urinary RHAMM and serum CA125
improved prediction of OC.
Taken together, the studies described herein suggest that RHAMM contributes to OC and
that further studies are warranted to further elucidate the clinical role of RHAMM in OC.

xii

Chapter 1: Introduction

Ovarian Cancer Overview
Commonly described as the “silent killer”, ovarian cancer (OC) is the fifth
leading cause of cancer related deaths in women and it has the highest mortality of all
gynecological malignancies1. In the Unites States, over 22,000 women will be diagnosed
annually with over 14,000 deaths from OC. Roughly one in seventy women will develop
OC in their lifetime with only a 45% five year survival2. When disease has undergone
metastatic spread, the survival rate drastically decreases from >90% in early stage disease
to less than 30% in late stage 1. Late diagnosis is largely a result of ambiguous symptoms
like bloating, stomach pain, back pain and irregular vaginal bleeding which can be
attributed to female irregularities. This prevents women from seeking medical attention
until it is too late and the disease has spread.

Risk factors for OC
The majority of OCs are sporadic in origin, but about 10% of all epithelial ovarian
carcinomas (EOC) are associated with a hereditary predisposition and are characterized
by an increased incidence and earlier onset of disease3. Therefore, family history (FH) is
the biggest risk for OC with the majority of hereditary OCs associated with breast cancer
susceptibility 1, (BRCA1), gene mutations (equating 1500 deaths annually)4,5,6,7.
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Epidemiological studies suggest that, besides race8 and FH of breast cancer (BC) or OC9 ,
events associated with ovarian surface epithelial (OSE) traumatization may result in
aberrant OSE growth leading to ovarian epithelial carcinogenesis 10,11,12,13. Specifically, it
has been suggested that incessant ovulation10,11,12,13,14 causes rapid cycles of OSE division
leading to errors in DNA replication and repair resulting in the inactivation and
overexpression of tumor suppressor genes and oncogenes, respectively15. Thus, increased
age, reproductive history (nulliparity), early menarche, late menopause and fertility drug
use increase the risk for OC. In contrast, suppression of ovulation by pregnancy, lactation
or oral contraceptive use decrease the risk for OC. Lifestyle factors including dietary fat
intake and smoking may also increase the risk for OC while dietary intake of vitamins
A,C, D and E may protect against OC16,17,18,19.

OC Subtypes
Despite the fact that the simple squamous-cuboidal OSE20,21 comprises only a
minute faction of the total ovarian mass and is traditionally thought to be the source of
OCs, the reasons for the propensity of OC development are still poorly understood.
Nonetheless, EOCs account for the majority of OCs. Due to the common embryologic
origin of OSE with the epithelia lining fallopian tube (FT), endometrium and cervix,
histologic subtypes of epithelial ovarian tumors include serous (SC), endometrioid (EC)
and mucinous (MUC) tumors22.
Malignant epithelial tumors comprise the most common types of OC, which includes SC,
EC, MUC and clear cell carcinoma (CCC). EC and CCC are believed to arise from the
endometriosis to the ovary23 and are associated with pelvic endometriosis24. EC typically
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presents in stage I with a unilateral mass still confined to the ovary and makes up about
10% of all OC cases24. CCC also presents as a unilateral mass in stage I or II, however if
diagnosed late, CCC often has a poor prognosis due to high prevalence of drug
resistance23. MUC is the rarest subtype, only comprising 3% of OC and often presents as
a large unilateral mass where bilateral nodes are often metastatic24. Historically, MUC
was commonly over-diagnosed due to the difficulty in distinguishing it from the
gastrointestinal tract, however advances in gross examination and immunohistochemical
staining markers have improved diagnostic accuracy 23.
Serous OC is most common type of EOC and makes up 70% of all cases of OC1.
There are two disease entities split into a dualistic model characterizing SC into type 1 or
type 2 OC by their resemblance to non-neoplastic epithelia and their somatic mutation
profile. Type 1 OCs are commonly low grade serous carcinomas (LGSC), relatively less
aggressive, often arise from precursor lesions and have specific molecular markers
including KRAS, BRAF, PTEN and CTNNB124. Conversely, type 2 OCs typically
present as high grade serous carcinomas (HGSC) and have an aggressive phenotype.
HGSC is the most common OC subtype and encompasses 60-80% of all ovarian
epithelial malignancies2. They are characterized by their chromosomal instability and
mutant p53 profile25,26.

The Recent Paradigm Shift in OC Etiology
While OC is traditionally thought to arise from the OSE, more recent evidence
suggests an alternate extra-ovarian origin for HGSC. HGSC has a poorly defined
pathogenesis, but is suggested to arise in the secretory epithelium of the distal FT which
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then easily transfers to the ovarian surface27,28,29,30. Pre-malignant lesions found in the
FTs prophylactically removed by salpingectomy as well as serous tubal intraepithelial
carcinomas (STIC)28 support the FT as the potential source of HGSC27,31. Further, HGSC
resembles tissue from the FT epithelium (FTE)32. However, despite many attempts,
precursor legions that lead to HGSC have not yet been identified and progression to
HGSC from a borderline low-grade tumor is rare.

Current Screening Methods and Biomarkers
As noted above, OC is a heterogeneous disease with multiple subtypes; all proven
difficult to detect at an early stage. To date, pelvic examination, ultrasound or circulating
cancer antigen 125 (CA125) serum levels are evaluated for OC detection. CA125 is
elevated in about 80% of OC patients, but fails to detect approximately 50% of stage 1
OC patients33,34. Serum CA125 is also frequently up-regulated in normal conditions,
benign reproductive disease and other cancer types35. Measuring CA125 levels has been
reported to cause patient anxiety and, in many cases, unnecessary surgery34.
To increase specificity of OC detection, multi-marker panels, such as
combinations of CA125 and human epididymis protein 4 (HE4), are being studied, but
require further validation36. HE4 has been shown to be elevated in the serum of OC and
endometrial cancer patients37. Although early reports of using sera HE4 as a biomarker
for OC appeared very promising, drawbacks have been noted. Like CA125, HE4 has
been shown to be elevated in other diseases such as lung cancer38, kidney fibrosis39 and
chronic kidney disease40. In addition, recent comparative analysis studies of HE4 and risk
for ovarian malignancy algorithm (ROMA), which scores the likelihood of malignancy
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being seen at surgery based off the results of HE4 assay, ARCHITECT CA 125 II and
menopause status, did not increase the detection of OC compared to CA125 alone.37
However, other applications of HE4 as a cancer biomarker are being investigated,
including its use to detect mucinous OC or disease progression of endometrial cancer.41
Other biomarkers are being evaluated in combination with CA125 to improve OC
detection, especially as that pertains to detecting early stage OC. For example, mesothelin
is elevated in ~70% of early stage serous OC, thereby improving OC detection rates by
CA125 alone42. Osteopontin (OPN) is under review as a combinatorial marker with
CA125 because OPN levels are histologically elevated in metastatic OC lesions43, serum
OPN levels decrease following cytoreductive surgery44 and an unique COOH-terminal
truncated OPN form has been reported to be elevated in OC patient urine45. Prior studies
have also suggested that measuring serum CA125 and lysophosphatidic acid (LPA)
together could be clinically important since LPA is found in ascites fluid of OC patients
and is also elevated in OC patient plasma46. Previous work in our lab reported that
urinary levels of the anti-apoptotic protein, Bcl-2, are elevated in early and late stage OC
with a tendency for increased urinary Bcl-2 levels with increasing tumor grade and stage.
We also showed that the combination of urinary Bcl-2 and serum CA125 increased
detection of both early and late stage OC patients.47 Lastly, the multi-biomarker panel
consisting of transthyretin (TTR), ApoA1, transferrin, beta 2 microglobulin and CA125
comprise the OVA1 test is already used clinically. This test best exemplifies the use of
multiple markers for the most effective results assessing the risk for OC in women who
present with an adnexal mass when radiological evaluation is unsure for malignancy48.
Despite many advances in medical research, neither the survival rate nor the
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treatment for OC has changed significantly for over 30 years. Optimal cytoreductive
surgery followed by platinum based chemotherapy remains the mainstay of therapy in the
management of advanced EOCs20. However, while the response rate to primary
chemotherapy can be as high as 76%, response rate is dramatically reduced after relapse
of disease49. Platinum resistance, defined as disease recurrence less than six months from
completion of therapy is an important prognostic predictor. Patients with platinumresistant tumors have a response rate of less than 10% when retreated with platinum
compounds50.

Alternative options also have poor response rates of 18-30%

51,52,53,54,55,56,57,54,58,59

. Together, this underscores the need to improve our understanding

of this disease and its etiology. Delineating key players driving OC could help elucidate
potential molecular diagnostic, prognostic and therapeutic targets.

RHAMM: Overview
Receptor for hyaluronan-mediated motility (RHAMM) belongs to a group of
hyaladherins, which share a common ability to bind to hyaluronan (HA). RHAMM is
located on chromosome 5, q arm, band 34, has a molecular mass of 85kDa and is 724
amino acids (AA) in length. Based on subcellular localization, RHAMM performs
multiple functions. Intracellularly, RHAMM is involved in microtubule spindle assembly,
thereby contributing to cell cycle progression60. On the extracellular surface, RHAMM
forms a trimeric complex with cluster differentiation 44 (CD44) and HA to activate cell
signaling pathways that promote migration, invasion and cell proliferation61. While
RHAMM is overexpressed in hematological malignancies and solid tumors arising from
prostate62, bladder63 and breast 64, it is not known whether RHAMM contributes to OC.
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Although minimally expressed in normal tissue, elevated RHAMM in BC and colorectal
cancer (CRC) is associated with poor clinical outcome and a more aggressive cancer
phenotype64,65.

RHAMM Domains
RHAMM consists of five known functional domains. Each domain consists of an
alpha helical coiled-coil separated by non-coiled sections. The first domain,
encompassing the N-terminus, is a non-essential domain that is often missing in the
truncated forms commonly seen in cancer. The function of domain 1 (D1) is not entirely
clear, however, it is hypothesized to negatively regulate the remaining functional
domains of RHAMM (D2-D5). D2 is reportedly a well conserved leucine-zipper motif
and has been shown to enable extracellular matrix (ECM) fibronectin to bind to cell
surface RHAMM, in order to promote podosome formation and cell motility66. The
function of D3 appears to be intracellular such that D3 encodes a region of RHAMM that
associates with intracellular mitogen activated protein kinase 1 (MEK1) to promote an
intracellular RHAMM/MEK1/extracellular signal regulated kinase 1(ERK1) complex61.
D4 has both extracellular and intracellular functions. D4 has been shown to mediate cell
motility and focal adhesion turnover by cell surface RHAMM while the D4 domain of
intracellular RHAMM encodes a region required for RHAMM to bind to ERK1, which
then activates the MAP kinase signaling cascade. Finally, D5 of extracellular RHAMM is
the HA binding domain composed of 9 to 11 amino acids ordered in a basic BX7B
motif67. This domain consists of basic amino acid sequences that bind solely to HA and is
key for cell motility driven by extracellular RHAMM. The D5 domain of intracellular
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RHAMM also binds to ERK1 and blocking this region prevents intracellular formation of
the RHAMM/ERK1 complex68.

RHAMM Splice Variants
RHAMM is known to have at least 5 splice variant isoforms. Full length
RHAMM (RHAMMv5) is the canonical form of RHAMM and consists of all 5
functional domains. Alternative splice variant RHAMMv5(-48bp) and RHAMMv5(147bp)69 truncations are seen variably overexpressed in different malignancies. Abnormal
quantities of the splice variant RHAMMv5(-48bp) compared to full length RHAMM are
associated with poor prognosis in multiple myeloma (MM), indicating deregulation of
these proteins in cancer can interrupt cell cycle progression, increase cell motility and
promote cell proliferation70.
Additionally, specific RHAMM isoforms contribute wound healing. For example,
immediately following injury in smooth muscle cells (SMCs), western immunoblots
(WB) detected a 65kDA RHAMM isoform band and 1 hour after injury, a 70kDA
RHAMM isoform demonstrating a progressive shift in RHAMM isoforms band
expression associated with advancing stages of wound healing71.
A minor transcript of RHAMM containing exon 4 (RHAMMv4) is transforming
when it is overexpressed and it is has been shown to mediate Ras/ERK signaling72. This
variant encodes a RHAMM isoform found on the cell surface and in the cytoplasm as
determined by epitope-tagging flow cytometry73 which has been shown to regulate RasERK signaling. This RHAMMv4 variant, then, plays different depending on its cellular
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location73 although are both intracellular and extracellular RHAMMv4 must be present
for ERK activation by platelet derived growth factor (PDGF)73.

Intracellular RHAMM
Functions of intracellular RHAMM are centered on mitotic spindle assembly, Ras
signaling and actin binding. RHAMMs association with centrosome formation66 and
mitotic spindle assembly74 strongly suggests intracellular RHAMM is important for cell
cycle progression. During post-mitotic interphase, RHAMMs’ degradation through
ubiquitination allows mitotic spindle assembly through the BRCA1/BARD1 complex to
mediate microtubule nucleation factor (TPX2) localization. RHAMMs’ ubiquitination
releases TPX2 from the spindle pole signaling aurora kinase A (AURKA) activation and,
thus, driving cell cycle progression75. Additionally, prolonged presence of RHAMM can
attenuate cell cycle progression by suppressing the protein complex cdc2/cyclinB1,
leading to cell cycle arrest76. Intracellular RHAMM has also been shown to directly bind
to ERK within the cell and can activate signaling downstream of RAS. Within the
cytoplasm, activated ERK can indirectly activate ribosomal protein S6 kinase (RSKs) and
ERK 1,2 translocation to the nucleus is critical for gene expression and DNA
replication77. This subsequently leads to the activation of transcription factors activator
protein 1 (AP-1), ETS domain-containing protein (ELK-1) and Myc that promote
downstream transcription of proteins involved with proliferation, migration, invasion and
adhesion. Lastly, RHAMM can associate with cell actin filaments as well as microtubules
to modulate the cytoskeletal network74. In this way, RHAMM/tubulin interactions
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influence MEK/ERK1,2 mediated instability of the mitotic spindle since the
stability/instability of this scaffold is critical for cellular proliferation and migration78

Extracellular RHAMM
Cell surface RHAMM has been reported to be key in activating signaling
cascades. Extracellular RHAMM binds to exogenous HA and acts as a co-receptor for
HA with CD4479 and PDGF80 which transduce the ERK 1,2 MAPKinase signaling
cascade. Subsequently, this activates Erk kinases73, Src81, protein kinase C, and focal
adhesion kinases72 (FAK) leading to increased migration, invasion, proliferation and
adhesion.
Upon binding with HA, RHAMM activates the phosphorylation of ERK 1,2. This
promotes ERK 1,2 translocation into the nucleus and contributes to the transcriptional
machinery of mitogenic genes82.

Downstream effectors of the ERK 1,2 pathway as

noted above then lead to tumor progression and invasion83 and cell motility after
injury71,81.

RHAMM in Wound Healing
Originally found secreted from embryonic chick heart fibroblasts, RHAMM has
been well studied as a key player in normal wound repair. When studying the HA content
surrounding excisional fetal skin wounds compared to incisional fetal skin wounds,
Lovvoran et al. 1998 reported markedly more CD44 and RHAMM immunohistochemial
(IHC) staining along the excisional wounds from day 1 to day 7 suggesting a role for
RHAMM in fibroplasia84. Similarly, fibroblasts from mice with a genetic deletion of
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RHAMM failed to heal scratch wounds > 3mm or invade HA supplemented collagen gels
in culture85. These researchers also showed that RHAMM is required for CD44 cell
surface localization, ERK1,2/CD44 trimeric complex and ERK 1,2 localization to the cell
nucleus confirming that RHAMM is essential for fibroblast mitogenic signaling in wound
repair. It is not surprising, then, that exogenous HA is now used extensively in the
dermatological field to decrease wound-healing time and scar formation through
RHAMM signaling pathway.
Interestingly, arterial wound repair and contraction by SMCs, characterized by
ECM remodeling and collagen deposition, is similarly mediated by HA/RHAMM as in
cutaneous wound repair. SMCs devoid of RHAMM demonstrated reduced adhesion to
collagen both in vivo and in vitro indicating that clinical inhibition of RHAMM may
reduce constrictive arterial remodeling and stenosis86.

RHAMMN in Breast Cancer
As demonstrated in BC, both intracellular and extracellular RHAMM contributes
to malignant disease. Early studies by Zhang et al. 1998 using real-time polymerase chain
reaction (RT-PCR) and IHC demonstrated RHAMM overexpression correlated with poor
prognosis in BC61. These researchers also reported that RHAMM overexpression in
human specimens correlated with overexpression of ERK and Ras, thereby confirming
the association of RHAMM with Ras and ERK previously seen in murine fibroblasts.
Similarly, using RT-PCR, florescent staining and subcellular fractionation, Assman et al.
1998 reported high levels of cytoplasmic RHAMM in BC cell lines87 which
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complemented IHC studies indicating overexpression of intracellular RHAMM in
invasive lobular carcinomas related to reduced overall patient survival time88.
As noted earlier, it has also been shown that, in invasive BC cell lines, RHAMM
forms a trimeric complex with CD44 on the cell surface to initiate the ERK 1,2 MAP
kinase pathway82. Sustained ERK 1,2/MAP kinase signaling driven by the
RHAMM/CD44 complex appears necessary to maintain and drive BC cell motility.
Likewise, particularly aggressive subsets of BC cells localized to local and lung
micrometastases demonstrate high levels of RHAMM located in extracellular
CD44/RHAMM complexes89.
Lastly, a link between RHAMM and BRCA1 has been identified by genetic
analyses which shows that a specific genetic variation in RHAMM appears to modify BC
risk in BRCA1 mutation carriers90. Blanco et al. 2015 showed that interaction between
RHAMM, BRCA1, TPX and AURKA was essential for microtubule organization that
contributes to the regulation of apicobasal polarity in BC cells. Modulation/loss of any of
these components appeared to increase risk for BC. Genotyping performed on 15,252
BRCA1 and 8,211 BRCA2 mutation carriers further confirmed the potential for
RHAMM as a BC susceptibility gene89.

RHAMM in Hematological Malignancies
Serological analysis of recombinant tumor cDNA expression libraries (SEREX)
identified RHAMM as a leukemia associated antigen (LAA) and tumor associated
antigen (TAA). LAAs elicit high-titer host immunoglobulin G (IgG) reactivity from Bcells stimulated by antigen-specific helper T cells since it is believed that LAAs may
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have epitopes recognized by CD4+ and CD8+ T lymphocytes91. Consequently, LAAs
present as potential antigenic structural targets for cellular immunotherapies and antibody
therapies. In this way, RHAMM is currently under investigation as a target for vaccine
immunotherapy to enhance the effect of graft-vs.-host benefits after stem cell
transplantation in AML patients.

Alternate Protein Secretion
The classical secretory pathway for protein export is well conserved, well defined
and requires an endoplasmic reticulum (ER) signal transport sequence typically located at
the protein N-terminus92. Newly translated proteins destined for extracellular secretion or
integration into the cell membrane travel through the rough ER and the Golgi complex
where they undergo similar modifications and are packaged for cell surface transport92.
Secreted proteins that lack a signal peptide sequence have been shown to employ
alternate export mechanisms including transporter channels, protein-release complexes,
flippase activity, exocytosis and membrane blebbing93. Interestingly, like RHAMM,
many proteins lacking an export peptide sequence have cytoplasmic functions that widely
differ from their extracellular function94. Additionally, cytoplasmic proteins that employ
alternate export mechanisms are often overexpressed and secreted as a result of cellular
transformation72,95,96. While it has been well established that RHAMM lacks a signal
export peptide sequence and there are no reports that is is secreted by alternate export
mechanisms, its mechanism for secretion is still unknown.
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Rationale
RHAMM is overexpressed in a number of cancer types. It is often associated with
an aggressive cancer phenotype due, in part, to its ability to promote cellular migration
and invasion, thereby contributing to poor clinical outcome. Herein, I sought to determine
if RHAMM similarly contributes to OC.

Central Hypothesis
Overexpression and secretion of RHAMM contributes to OC disease progression.
Three specific aims are proposed to test this hypothesis.

Specific Aims
Aim 1. Determine the contribution of RHAMM to OC progression.
To begin to assess the role of RHAMM in OC, I will first demonstrate overexpression of
RHAMM in clinical samples of OC and then, using an in vitro cell culture model system,
I will determine whether RHAMM promotes OC cell migration/invasion.

Aim 2. Delineate the mechanism of RHAMM secretion in OC.
Although RHAMM has discrete intra- and extracellular functions that could promote
tumor progression, it lacks a signal peptide transport sequence. Therefore, the mechanism
by which RHAMM is secreted is unknown. Using computational analyses supported by
in vitro validation, I will suggest an alternate, signal peptide transport sequenceindependent mechanism by which RHAMM may be secreted by OC cells.
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Aim 3. Evaluate RHAMM as a novel urinary biomarker for OC.
Since RHAMM is only loosely tethered to the external cell surface, elevated levels of
RHAMM may be found in bodily fluids of OC patients. Therefore, I will measure and
evaluate the potential of urinary RHAMM levels among healthy controls, women with
benign gynecologic disease and OC to serve as a novel OC biomarker.
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Chapter 2: RHAMM is overexpressed in OC

Background
As discussed in chapter 1, intracellular RHAMM is involved in microtubule spindle assembly
and it contributes to cell cycle progression1. On the extracellular surface, RHAMM forms a
trimeric complex with cluster differentiation 44 (CD44) and HA to activate extracellular signal
regulated kinase 1/2 (ERK1/2) cell signaling pathways to promote migration, invasion and cell
proliferation2. Although minimally expressed in normal tissue, RHAMM is overexpressed in
hematological malignancies and solid tumors arising from prostate3, bladder4 and breast 5. In
addition, elevated RHAMM in breast cancer (BC) and colorectal cancer (CRC) has been
associated with poor clinical outcome and a more aggressive cancer phenotype5,6. 7,8. In order to
determine whether Rhamm might likewise contribute to ovarian cancer progression, I began my
studies by determining whether RHAMM is overexpressed in clinical specimens.

Methods
Clinical Specimens
With University of South Florida Institutional Review Board approval and patient consent,
tissues were collected from a cohort of women who had undergone primary surgery with
complete surgical staging for epithelial ovarian cancer (EOC) or borderline tumors at the Moffitt
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Cancer Center and the University of South Florida (Table 2.1). This gynecologic oncology
database was also used to select women who had undergone oophrectomy due to cystadenoma or
had their ovaries removed for unrelated pathology. All tissue specimens were di-identified prior
to release for research. All tissues were fixed with 10% formalin, paraffin-embedded, sectioned
and stained with hematoxylin and eosin (H & E). The slides were reviewed by Drs. Champeaux
and Nicosia to confirm histologic diagnosis according to the International Federation of
Gynecology and Obstetrics (FIGO) classification system.

Immunohistochemistry
For immunohistochemical (IHC) studies, formalin-fixed paraffin sections were cut at 3
microns and dried overnight at room temperature (RT) then deparaffinized and rehydrated.
Sections were incubated in BLOXALL™ Blocking Solution (Vector Laboratories, Burlingame,
Ca) for 20 minutes to block endogenous peroxidase activity. Antigen retrieval was achieved by
placing slides in 1× solution Antigen Unmasking Solution (Vector Laboratories, Burlingame,
Ca) brought to a boil and maintained at 95 °C for 30 minutes on a hot plate. Specimens were
then immunostained using Rabbit Anti-Human CD168 (ThermoFisher Scientific, Waltham, MA)
primary antibody (1:100) for 1 hour and Vectastain® Elite ABC Kit (Vector Laboratories)+
Dako's EnVision™ + HRP Rabbit (DAB+) kit according to the manufacturer's instructions, then
counterstained with modified Mayer's haematoxylin, dehydrated through graded alcohol, cleared
with xylene, and mounted with resinous mounting medium. To control variability, all samples
were stained at the same time and with the same lot of reagents. Breast carcinoma (BC) was used
as an internal positive control while negative controls were obtained by substitution of primary
antibody with normal rabbit serum.
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Evaluation of RHAMM staining
A minimum of 100 cells were counted at a final magnification of 400X per tissue section.
Immunostaining of RHAMM was scored based on average percent of positive epithelial cells (0,
negative or no staining; 1+, <30%; 2+, 30-50% and; 3+, >50%) and on staining intensity
(negative, weak, moderate and strong). Cellular localization of RHAMM was also assessed as
cytoplasmic, membranous, nuclear or stromal.

Images
Images were acquired on a digital Olympus DP-20 camera under a Leica dmire2 microscope.
Olympus micro imaging software CellSens platform was used to acquire and process images.
Images were taken with a final magnification of 100x and 400x.

Results
RHAMM is overexpressed in OC.
Immunological staining was performed on 44 tissue sections from 36 women. The sample
population provided sections of normal ovarian surface epithelium (OSE) (n=5), serous OC
(n=22), omental metastasis (n=7), lymph node metastasis (n=1), endometrioid OC (n=1), clear
cell carcinoma of the ovary (CCC) (n=1), mucinous OC (n=1) and normal fallopian tube (FT)
(n=6). Though these samples comprise a small pilot study, they are representative of a typical
clinical practice with regards to histological distribution (Table 2.1). BC was used as a positive
control (n=2).
Overall, I found that 91% (20/22) of serous OC stained positively for RHAMM with levels of
staining intensity ranging from weak (<30% from each field, N=4), moderate (30-50%, N=7) to
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strong (>50%, N=9) while 0% (0/5) of normal OSE stained for RHAMM. (Figure 2.1, Table 2.2)
Staining patterns, as depicted by intense, punctate/diffuse cytoplasmic staining, seen in BC
positive control were consistent with previous reports of RHAMM in BC where intense staining
is predominately in the cytoplasm and nucleus, but negative in the stroma 9,10.
RHAMM expression was predominately localized in the cytoplasm in 91% (20/22) of the
serous OC specimens while the surrounding stromal tissue remained negative (Figure 2.1, Table
2.3). Further, membranous staining was seen in 27% (6/22) of serous OC (Figure 2.1D, E, F &H)
and 18% (4/22) of serous OC specimens demonstrated nuclear staining (Figure 2.1H). Well
differentiated (WD) serous OC displayed membranous RHAMM staining localized to the apical
cell surface (Figure 2.1D, E, F & H). Interestingly, I noted RHAMM staining in OC cysts
(Figure 2.1D&F).
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Figure 2.1: RHAMM staining is elevated in OC tissue specimens (Continued on Next Page)
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Figure 2.1: RHAMM staining is elevated in OC tissue specimens
Representative photographs of IHC staining for RHAMM [anti-CD168 polyclonal antibody
(PA5-32309) with a 1:100 dilution] in B) normal, C) low malignant potential (LMP), D&E) WD
and F&G) PD serous OC. PD breast carcinoma was used as a positive control (A). Control
sections were incubated with non-immune serum. Original magnification 100x and 400x.

RHAMM staining intensity increases with grade in serous OC.
Poorly differentiated (PD) OC sections displayed intense punctate staining while WD OC
displayed mostly weak and homogenously diffuse staining (Figure 2.1, Table 2.2). Although
percentages of positive staining were similar in WD (8/10 or 80%) and PD (14/15 or 93%)
serous OC, increased staining intensity correlated with increasing grade (Figure 2.1, Table 2.1).
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RHAMM is overexpressed in metastatic disease.
When I compared RHAMM staining in primary tumors and their respective metastases for eight
serous OC patients, I found positive RHAMM staining in 88% (7/8) of the primary tumors and
88% (7/8) of their omental or 100% (1/1) of lymph node metastases. Matching RHAMM
staining percentages, intensities and cellular localization were seen in primary tumors and their
respective metastases among all 8 patient samples (Figure 2.2, Table 2.4).

Figure 2.2: Primary and metastatic OC stain equally for RHAMM
Representative photographs of IHC staining for RHAMM in multiple sections from within the
same patient of A) normal, B) primary serous adenocarcinoma and C) omental metastatic tissue.
Control sections were incubated with non-immune serum. Original magnification 100x and
400x.
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RHAMM is variably expressed in different histological subtypes.
Additionally, I examined other histological subtypes of OC and found that endometrioid
OC was devoid of RHAMM staining and only weakly positive RHAMM staining was seen in
mucinous OC, but RHAMM stained intensely in CCC (Figure 2.3). The CCC specimen
demonstrated intense, punctate nuclear RHAMM staining in contrast to predominately
cytoplasmic and membranous staining seen in serous OC. Weakly, positive RHAMM staining
was seen in the mucinous OC and staining appeared localized to the apical membranous cell

Endometrioid

surface (Figure 2.3).

Figure 2.3: RHAMM is differentially expressed among OC histological subtypes.
(Continued on Next Page)
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Figure 2.3: RHAMM is differentially expressed among OC histological subtypes.
Representative photographs of IHC staining for RHAMM from tissues of CCC, mucinous OC
and endometrioid OC. Control sections were incubated with non-immune serum. Original
magnification 100x and 400x.

Normal fallopian tube epithelium (FTE) stains intensely for RHAMM.
Compared to normal OSE, which failed to stain for RHAMM, I found 100% (6/6) positive
RHAMM staining in all normal FTE specimens examined (Figure 2.4). There was moderate to
strong staining limited to the surface of the fimbrial epithelium, cytoplasm and nucleus while
stromal elements did not stain for RHAMM. Regions with the strongest staining were
predominately at the apical surface of the fimbrial epithelial cells (Figure 2.4).

**
**

Figure 2.4. Normal FT stains intensely for RHAMM
Representative photographs of IHC staining for RHAMM in normal FT. Control sections were
incubated with non-immune serum. Original magnification 100x and 400x.
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Conclusion
Overall survival of OC has not improved for several years due to poor understanding of its
pathogenesis, late diagnosis, emergence of drug resistance and lack of reliable biomarkers.
Consequently, in order to better elucidate the etiology of this disease, the aim of this pilot study
was to determine if, like other cancer types, RHAMM is overexpressed in OC and whether
RHAMM could, likewise, promote OC progression.
I show for the first time that RHAMM expression is elevated in serous OC compared to
normal OSE. I observed 91% of serous OC patients demonstrated positive RHAMM staining
which was localized primarily to the cytoplasm, cell membrane, cystic fluid and, occasionally,
the nucleus. RHAMM staining appeared to be specific to epithelial tumor cells since the stroma
failed to stain. I also showed that RHAMM staining intensity increased with increasing cancer
grade. Levels of RHAMM appear to be dependent upon the extent of differentiation where WD
specimens demonstrated intense, punctate staining while PD specimens typically demonstrated
intense, but rather diffuse RHAMM staining. High levels of RHAMM in aggressive colorectal
cancer tumor budding cells are associated with higher grade, poor survival, increased lymphatic
invasion and nodal metastasis11. Additionally, invasive BC cell lines express higher levels of
RHAMM12 and IHC staining in 189 mammary carcinomas revealed that elevated RHAMM in
lobular carcinomas is correlated with more invasive behavior and reduced overall patient
survival time10. Therefore, high levels of RHAMM seen in high grade OC could contribute to an
invasive phenotype. High levels of HA have been reported in the ovarian tumor
microenvironment13, such that HA may mediate RHAMM overexpression and activation in OC
leading to cell transformation14, initiation of the ERK1/2 MAPkinase pathway15 and cell
proliferation16,17.
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Upon binding to HA, extracellular RHAMM activates the ERK1/2 MAP kinase pathway
leading to the transcription and translation of proteins associated with migration and invasion.
Downstream effectors of this pathway include transcription factors AP-1 and SP1, known to play
roles in DNA damage repair, cell cycle control, migration and invasion18. Cytoplasmic RHAMM
binds to actin and microtubules in the cytoskeleton and plays a role in cell cycle progression
through the G2M phase19. Lack of RHAMM in normal tissue suggests elevated RHAMM in OC
may contribute to an invasive phenotype in OC.
Though only few samples of endometrioid, mucinous and CCC were available, my samples
reflect the incidence of OC histosubtypes. Of OC malignancies, CCC, mucinous and
endometrioid only comprise about 5%, 10% and 15% of cases, respectively20. Endometrioid OC
failed to stain for RHAMM and mucinous OC stained weakly in agreement with the lesser
aggressive clinical behaviors of these OC histosubtypes. In contrast, CCC showed a distinct
pattern of intense nuclear RHAMM staining. Recent evidence has shown intense cytoplasmic
IHC staining of Naspin A as a specific marker for CCC21. Given that CCC can require a specific
course of treatment and careful monitoring due to its poor prognosis and resistance to
chemotherapeutics22, that addition of nuclear RHAMM staining could expand the known
molecular profile of CCC.

However, it is possible that these single incidences do not

representatively reflect the population of OC cases, therefore more samples would be needed to
determine RHAMM staining in endometrioid, mucinous and CCC histosubtypes.
Since recent studies suggest that high grade serous ovarian cancer (HGSOC) arises from the
FTE 23, I also subjected normal FTE to IHC staining for RHAMM. Distinct molecular markers of
HGSOC include dysregulation of wild type p53 (wtp53) which is seen in about 96% of HGSOC
cases. Dysregulation of wtp53 can occur as gain of function (GOF) mutations, termed TP53
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mutations. These mutations often lead to the acquisition of oncogenic functions, abrogating the
cell cycle constraints controlled by wtp5324. Since wtp53 is a negative transcriptional regulator
of RHAMM protein7, RHAMM mRNA and protein levels are normally down regulated in the
presence of wtp53. Conversely, I speculate that dysregulation of wtp53 in OC could drive
overexpression of RHAMM. Interestingly, RHAMM was strongly evident in all of the normal
FT specimens examined, showing the most intense staining at the apical end of the fimbriae.
Reports of morphological variation among normal FTE cells25 and presence of wt p53 mutations
in non-suspicious FTE26, suggest that underlying p53 mutations present in apparently normal
FTE could modulate RHAMM expression prior to visualization of overt changes associated with
malignant transformation. Dysregulation of RHAMM in the FT in concert with wtp53
mutations could contribute to pre-malignant lesions and, thus, drive oncogenic progression to
HGSOC.

Table 2.1 – Summary of the patient cohort.

N=36 Patients

Low Grade
Well Differentiated

High Grade
Poorly Differentiated

Normal
Ovarian Cancer
Histology

5
25

10

15

Serous
Endometrioid
Mucinous
Clear Cell

22
1
1
1

7
1
1
1

15

3
3
11
8

3
0
5
2

0
3
6
6

6

N/A

N/A

2

1

1

Stage
I
II
III
IV
Other
Normal Fallopian
Tube
Breast Cancer
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Table 2.2- Quantification of RHAMM IHC.

%
Staining

Staining
Intensity

N

Positive

<30%

30-50%

>50%

Weak

Moderate

Strong

Normal
Cancer
Histology

5
25

0
22/25

5/25

8/25

9/25

6/25

6/25

10/25

Serous
Endometrioid
Mucinous
Clear Cell
Grade
Low
High

22
1
1
1

20/22
0
1/1
1/1

4/22
0
1/1
0

7/22
0
0
1/1

9/22
0
0
0

5/22
0
1/1
0

6/22
0
0
0

9/22
0
0
1/1

10
15

8/10
14/15

3/10
2/15

4/10
4/15

1/10
8/15

4/10
2/15

2/10
4/15

2/10
8/15

3
3
11
8

3/3
3/3
9/11
7/8

1/3
1/3
2/11
1/8

2/3
1/3
3/11
2/8

0/3
1/3
4/11
4/8

6

6/6

0

1/6

5/6

1/3
0/3
4/11
1/8
1/6

1/3
2/3
1/11
2/8
2/6

1/3
1/3
4/10
4/8
3/6

Stage
I
II
III
IV
Fallopian
Tube

Table 2.3- Subcellular localization of RHAMM.

Localization
Normal
Cancer
Histology
Serous
Endometrioid
Mucinous
Clear Cell
Grade
Low
High

N

Positive Cytoplasm

Membrane

Nuclear

Stroma

5
25

0
22/25

21/25

7/25

5/25

1/25

22
1
1
1

20/22
0
1/1
1/1

20/22
0
1/1
0

6/22
0
1/1
0

4/22
0
0
1/1

1/22
0
0
0

10
15

8/10
14/15

7/10
14/15

2/10
5/15

2/10
3/15

1/10
0

3
3
11
8

3/3
3/3
9/11
7/8

2/3
3/3
9/11
7/8

0
1/3
4/11
2/8

1/3
1/3
2/11
1/8

6

6/6

5/6

5/6

2/6

0
0
0
1/8
2/6

Stage
I
II
III
IV
Fallopian
Tube
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Table 2.4- RHAMM immunostaining patterns shown in primary and metastatic tumors.

Patient

Description

Grade

Staining

P1
P1
P1
P2
P2
P3
P3
P3
P4
P4
P5
P5
P6
P6
P7
P7
P8
P8

Normal Ovary
Primary OC
Omental metastasis
Primary OC
Omental metastasis
Normal Ovary
Primary OC
Omental metastasis
Primary OC
Omental metastasis
Primary OC
Omental metastasis
Primary OC
Omental metastasis
Primary OC
Omental metastasis
Primary OC
Lymph node metastasis

low
low
low
low
high
high
high
high
high
high
high
high
high
high
high
high

+
+
+
+
+
+
+
+
+
+
+
+
+
+

%
Staining
0
1
1
2
2
0
3
3
1
1
0
0
3
3
2
2
2
1

Intensity
Negative
Weak
Weak
Weak
Weak
Negative
Strong
Moderate
Weak
Weak
Negative
Negative
Strong
Strong
Moderate
Moderate
Moderate
Weak
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Chapter 3: RHAMM promotes OC cell migration and invasion

Background
Cellular migration and invasion are essential for metastatic spread contributing to disease
progression and poor clinical outcome. Originally cloned in 1992, multiple studies have
demonstrated a role for RHAMM in cell motility1,2,3 and malignant transformation4,5. Having
shown that RHAMM is overexpressed in OC (Chapter 2) similarly to a number of solid6,7,8,9,10
and hematological11,12 cancers, herein I sought to establish an in vitro OC model in order to
determine whether RHAMM overexpression in OC cells likewise modulates OC cell migration
and invasion.

Methods
Cell Culture
The SV 40-Large T-Ag-transfected human OSE (HIOSE-118 and HIOSE-121), normal human
dermal fibroblasts (HDF), OC (OVCAR5, OV90, SKOV3 and ES-2), BC (MCF-7) and
cervical cancer (OV2008 and C13) cell lines (Table 3.1) were cultured in Medium 199/MCDB
105 (Sigma, St. Louis, MO) with 5% fetal bovine serum and gentamicin. All cells were
incubated at 37° C with 5% CO2.
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Western Blot
Cells were washed in PBS, trypsinized, pelleted, and washed 1-2 times in cold PBS. Cells were
lysed in CHAPS buffer and 30 µg of protein was separated via 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred to polyvinylidene
fluoride (PVDF) membranes and blocked in 5% milk in Tween 20-Tris buffered saline. Blots
were incubated in their respective primary antibodies overnight, followed by incubation with a
horseradish peroxidase-(HRP-) conjugated secondary antibody (Fisher, Pittsburgh, PA), and
developed via enhanced chemiluminescence substrate (ECL) (Pierce/Fisher, Pittsburgh, PA).
Antibodies used were monoclonal rabbit anti-CD168 RHAMM antibody (abcam®, Cambridge,
MA)

Human HMMR/CD168/ RHAMM Sandwich enzyme-linked immunosorbent assay (ELISA)
RHAMM ELISA (LifeSpan BioSciences, Inc., Seattle, WA) was performed according to the
manufacturer’s recommended instructions for cell culture lysates. For analyses of conditioned
medium, volumes of conditioned medium equivalent to 1x106 cells were concentrated by
centrifugation at 16,000 x g using 30,000 kDa microfilters (Millipore, Bedford, MA). All
samples were thawed to room temperature, centrifuged to remove particulate matter and volumes
of 100ul normalized by cell number were examined by ELISA. Plates were read using a
microplate reader (BioTek ELx800) with a 450nm wavelength filter.

Real-time polymerase chain reaction (qPCR)
Cells were treated with TRIzol reagent from Invitrogen (Carlsbad, CA) and ribonucleic acid
(RNA) was isolated according to the manufacturer’s instructions. To generate single-stranded
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complementary DNA (cDNA), the Applied Biosystems GeneAmp RNA polymerase chain
reaction (PCR) Core Kit (Foster City, CA) was used with 3 ug/mL total RNA using Biometra
UNO-thermo-block and Perkin-Elmer-GeneAmp PCR system 9600. qPCR was carried out with
SYBR Green Universal Master Mix (Applied Biosystems), cDNA, and primers. Primers used
were

sense

5’-

ACTCCGCTGTCAGCTTGCTAAA-3’

and

antisense

5’-

AATGGGGTCTTCAGGGCAAA- 3’ (Sigma- -aldrich Oligoarchitect®, St. Louis, MO) and
GAPDH (All-in-One™ qPCR Primer for NM_002046.3, GeneCopeia, Rockville, MD) as
control. Amplification was performed with 40 cycles of denaturation (95°C, 10 sec), annealing
(60°C, 20 sec), and extension (72°C, 15 sec) using a Bio-RAD Chromo4 Real Time PCR
Detector using Opticon Monitor 3 program. Levels of RHAMM were normalized to the GAPDH
message values and the fold difference was determined by dividing the threshold cycle (Ct) value
by the reference sample.

Cell Transfection
One million cells were transfected using the Nucleofector device (Amaxa, Gaithersburg, MD)
with 30nM of siRHAMM Silencer® select validated siRNA that targets all 4 sequenced
RHAMM variants (ThermoFisher Scientific, Waltham, MA) or scramble (scr) RNA
(ThermoFisher Scientific, Waltham, MA). Briefly, 1 × 106 cells were mixed with 2 µg of the
appropriate plasmid in 100 µL of Nucleofector solution (kit #VCA-1003). The cell suspensions
were transferred to electroporation cuvettes and transfected using program X-005 on the
Nucleofector device for cell lines (HIOSE-121, OV2008 and OCAR5) and program A-023 for
(OV90) OC cell line.
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To estimate overall transfection efficiency, Green Fluorescent Protein (GFP)-transfected cells
were visualized and photographed 24 h post-transfection using a digital camera-equipped
fluorescence microscope. Parallel cultures of cells transfected with siRHAMM or scrRNA
were incubated overnight at 37° C with 5% CO2 and collected the following day for analysis.
RHAMM silencing was confirmed by WB.

Quantification of Cell Proliferation
In order to account for differences in cell proliferation with or without RHAMM inhibition, cell
number was counted using a hemocytometer in order to estimate viable cells per mL. The
average cell count was taken from each of the 5 (4x4) square sets and was multiplied by 10,000.
Cell numbers were counted before, immediately after, 24h after and 48h after transfection. Each
data point was the mean of at least 3 experiments done in triplicate.

Cell Migration Assay
OV90 and HIOSE-121 cells were serum starved overnight (ON) and then transfected with
siRHAMM or scr RNA. Untransfected cells served as additional controls. One million cells were
washed with PBS, trypsinized and aliquoted onto silicone well inserts (Ibidi USA Inc.,
Fitchburg, WI). The cells were incubated ON to create a monolayer of adherent cells. The
silicone insert was removed after 24h to create the scratch wound. Images were taken at 0h
(silicone insert removal), 24h and 48h.
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Cell Invasion Assay
As per the manufacturer’s protocol, OV90, OVCAR5 and HIOSE-121 cells were serum starved
ON, untransfected cells and cells transfected with siRHAMM or scrRNA were maintained for
24h. The following day, the cells were washed with PBS, trypsinized and recounted. Transwell
inserts from the CytoSelect™ 96-Well Collagen Cell Invasion Assay (Cell Biolabs, Inc., San
Diego, CA) were warmed and rehydrated with serum-free media for 1h before adding cells. Cell
suspensions were added to transwell inserts and placed in a feeder tray containing 10% FBS
media, covered and incubated for 24h. Cells that had invaded through the collagen coated
transwell inserts onto the underlying membrane were dissociated and lysed. Lysed cells are
detected with CyQuant® GR Dye and quantified using a fluorescence plate reader at 480 nm/520
nm.

Statistics
For real time PCR, error bars illustrate RQmin and RQmax, which were calculated as: RQave
divided by (standard deviation^ student’s t value at the 95% confidence interval, for 5 degrees
freedom) and RQave times (standard deviation^ student’s t value at the 95% confidence interval,
for 5 degrees of freedom), respectively. This range represents the 95% confidence level. For
ELISA, proliferation and invasion studies, results were analyzed using the student T-test.
p≤0.05* and p≤0.0001** was considered statistically significant.
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Results
RHAMM is Elevated in and Secreted by OC Cells
Since OC patient specimens stained intensely for RHAMM (Chapter 2), I sought to
establish an in vitro model in which to study the function of RHAMM for OC progression. I
measured levels of RHAMM mRNA, cellular protein and secreted RHAMM protein into
concentrated conditioned media (CCM) by qPCR, WB and ELISA, respectively, in MCF-7,
OV2008, C13, OVCAR5, OV90, SKOV3, ES-2, HIOSE-118, HIOSE-121 and HDF cells. qPCR
revealed varying levels of RHAMM mRNA among the cell lines (Figure 3.1A). However,
protein levels of both cellular and secreted RHAMM were consistently elevated, up to 5x, in OC
cell lines compared to IOSE cells as measured by WB (Figure 3.1B-D). Protein bands of CCM
were quantified by densitometric analysis and shown as a trim signal measured by ImageJ
computer software program. CCM was compared to a positive control OV2008 cell lysate
(Figure 3.1C). Using ELISA, RHAMM levels in CCM, normalized for cell number, were
measured and found to be higher in showing higher OC cells than normal OSE (Figure 3.1D).
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Figure 3.1 RHAMM is overexpressed in cultured OC cells.
Message and protein levels of RHAMM were measured by qPCR (A), WB (B,C) and ELISA (D)
in HIOSE-118, HIOSE-121, HDF, MCF-7, OV2008, C13, OVCAR5, SKOV3, OV90 and ES-2
cells. A) qPCR was performed on isolated mRNA using RHAMM sense and anti-sense primers
to measure RHAMM expression. WB was performed on protein cell lysates (B) and CCM (C)
WB were quantified by densitometric analysis (Image J software for trim signal value) of target
protein bands to GAPDH levels where OV2008 cell lysate was used as a positive control. ELISA
was performed on CCM normalized for cell number (D). Results are expressed as the average
RHAMM level ± S.E where p≤0.05* and p≤0.0001** was considered statistically significant.
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RHAMM does not promote OC cell proliferation
Since RHAMM contributes to cell cycle progression and, hence, cellular proliferation
through its nuclear role, I sought to determine whether inhibition of RHAMM negatively
impacted OC cell growth. HIOSE-121, OVCAR5 and OV90 cells were serum starved ON, then
transfected with siRHAMM or scrRNA with untransfected cells serving as additional controls. I
found that cell number was not significantly affected by loss of RHAMM expression after 24h or
48h after transfection (Figure 3.2). Successful transfection was validated by WB (Figure 3.2 DF).
RHAMM Promotes OC Cell Migration
In order to determine RHAMMs’ contribution for OC cell migration, HIOSE-121 and
OV90 cells were serum starved ON, then transfected with siRHAMM RNA and scr RNA while
untransfected cells served as additional controls. Following transfections, cells were subjected to
scratch assays and monitored for ‘wound repair’ for 48 hours. I found that the migration of
normal OSE cells (HIOSE-121) was unaffected by abrogation of RHAMM. Regardless of
treatment (siRHAMM RNA, scrRNA or untreated controls), all OSE cells equally filled in the
scratch gap within 48h (Figure 3.3A). In contrast, reduced OV90 cell migration was noted in
cells transfected with siRHAMM RNA compared to untreated controls or cells transfected with
scrRNA as early as 24h (Figure 3.3B). By 48h untreated and scrRNA treated OV90 cells had
completely filled the scratch gap while OV90 cells transfected with siRHAMM RNA had only
filled approximately 32% of the scratch gap (Figure 3.3B).
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Figure 3.2 RHAMM does not promote OC cell proliferation.
The number of viable (A) HIOSE-121, (B) OV90 and (C) OVCAR5 cells transfected with
siRHAMM RNA, scr RNA as well as untransfected cells was determined by cell counts
performed at the time of transfection (0h) and 24h and 48h after transfection. The results are
expressed as the average cell number ± S.E. Each data point was the mean of at least three
experiments done in triplicate. p≤0.05* was considered statistically significant. Successful
silencing of RHAMM was confirmed by corresponding WB (D-F).
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Figure 3.3 RHAMM promotes OC cell migration. (Continued on Next Page)
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Figure 3.3 RHAMM promotes OC cell migration.
Representative images from scratch assays of normal HIOSE-121 (A) and OC OV90 (B) cells
transfected with siRHAMM RNA or scrRNA and untransfected cells. Images were taken
immediately after the silicone insert was removed (0 hrs), 24 hrs and 48 hrs. 100x magnification.

RHAMM Enhances OC Cell Invasion
In addition to mediating cell migration, I wanted know if RHAMM also promoted OC
cell invasion. HIOSE-121, OV90 and OVCAR5 cells were serum starved O/N, transfected with
either scr RNA, siRHAMM RNA or untransfected (as control) and then subjected to invasion
assay using collagen coated Boyden chambers. My results show that regardless of treatment
(siRHAMM RNA, scrRNA or untreated controls), all OSE cells equally migrated through the
Boyden chambers (Figure 3.4). However, there was significantly less invasion by siRHAMM
RNA treated OV90 and OVCAR5 cells compared to their scrRNA and untreated control
counterparts (Figure 3.4). Invasion by siRHAMM RNA transfected OV90 cells was reduced by
39.7% and 47.6% compared to untreated and scrRNA treated OV90 cells, respectively.
Likewise, invasion by siRHAMM RNA transfected OVCAR5 cells was reduced by 65.9% and
58.9% compared to untreated and scrRNA treated OVCAR5 cells, respectively. Successful
inhibition of RHAMM expression was confirmed by WB.
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Figure 3.4 RHAMM contributes to OC cell invasion.
HIOSE 121, OV90 and OVCAR5 cells transfected with either siRHAMM RNA, scrRNA or left
untreated were seeded onto a Cytoselect collagen-coated transwell membranes in triplicates for
24h. Cells that invaded through the collagen gel onto the underlying membrane were detached
and lysed. Lysed cells are detected with CyQuant® GR Dye and quantified using a fluorescence
plate reader at 480 nm/520 nm. Results are represented as a mean of RFU ± S.E. p≤0.05*

Conclusion
It is well established that RHAMM plays a profound role in cell migration associated
with normal wound healing13,14. RHAMM also contributes to a more aggressive phenotype
requiring migratory and invasive cell capabilities seen in malignancies such as breast15, prostate9,
bladder8 and colon10 cancer. Having shown that RHAMM is overexpressed in OC (Chapter 2)
similarly to a number of solid and hematological cancers, herein, I sought to establish an in vitro
OC model in order to determine whether RHAMM overexpression in OC cells likewise
modulates OC cell migration and invasion.
Using normal HIOSE and a variety of cancer cell lines, I have been able to show that
cellular levels of RHAMM message and protein are elevated in OC cells lines. Likewise,
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RHAMM levels were elevated in the CCM of OC cultures indicating that in vitro OC cell lines
represent an appropriate model system with which to begin to define the mechanism(s) by which
RHAMM may contribute to OC progression.
Surprisingly, when RHAMM expression was inhibited by siRNA silencing technology, I
was unable to detect any significant change in OC cell proliferation. Given that the multiple
functions associated with RHAMM are defined not only by its subcellular localization, but also
by differences in RHAMM isoform expression, it is possible that the predominant RHAMM
isoform expressed in these cell lines was not functionally associated with cell cycle progression.
Since cultured HIOSE cells and their in vivo counterparts failed to express significant
amounts of RHAMM protein, it was not unexpected that silencing RHAMM in HIOSE cells did
not result in any changes in cellular proliferation. It should be noted, however, that I was able to
detect RHAMM mRNA in HIOSE cells, but differences in RNA stability and processing
between HOISE and OC cells could limit the degree to which HIOSE RHAMM RNA is
translated into protein compared with OC RHAMM RNA species. In contrast, I found a
significant decrease in the migratory and invasive capabilities of OC cells as a result of RHAMM
inhibition suggesting that RHAMM may drive OC progression using similar cellular migratory
and invasive mechanisms as reported in other cancer types.
Lastly, it is important to note that in addition to wound healing, inherent RHAMM
expression/function manifests during embryogenesis where it is essential for proper
developmental processes16,17,18 especially as that pertains to contributing to and maintaining
human embryonic stem cell (hESC) pluripotency. High levels of extracellular RHAMM are
evident at very early stages of embryonic development while high levels of both cell surface and
intracellular RHAMM are found high in later developmental stages16. Studies have shown that
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RHAMM is responsible for the migration to and differentiation of hESCs16 within the cranial
neural crest17. Therefore, it is not surprising that re-capitulation of embryonic events resulting in
the re-activation of RHAMM could contribute to cellular transformation and cancer progression
in OC.

Table 3.1 : Cell Line Descriptions
Cell Line

Cell Type

HIOSE-118/ HIOSE-121

Normal OSE cells with FH / without FH

HDF

Normal human dermal fibroblasts

MCF-7

Breast adenocarcinoma

OV2008/C13
SKOV3

Human papillomavirus-related cervical
squamous cell carcinoma
Ovarian serous cystadenocarcinoma

ES-2

Ovarian clear cell adenocarcinoma

OV90

Ovarian adenocarcinoma

OVCAR5

High grade ovarian serous adenocarcinoma
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Chapter 4: Unconventional Secretion of RHAMM

Background
Reports of RHAMMs’ tumorigenic functions are related to its contribution to increased
cellular migration1,2, invasion3,4 and cell proliferation5. However, its functions are dictated by its
location6. Intracellular functions of RHAMM are related to mitotic spindle organization
influencing cellular proliferation while extracellular RHAMM binds to HA in the tumor
microenvironment activating downstream MAP kinase signaling7. RHAMM, discovered in
medium of sub-confluent chick heart fibroblasts1, has no signal peptide transport sequence and,
therefore, is not secreted by cells in a traditional manner. Likewise, there have not been any
reports of RHAMM secretion by alternate methods such as transporter channels, protein
chaperone complexes, flippase activity, exocytosis or membrane blebbing. Therefore, the
mechanism by which RHAMM is secreted remains unknown. Having shown that OC cells
overexpress RHAMM both in vivo (Chapter 2) and in vitro (Chapter 3) and that secretion of
RHAMM by OC cells contributes to cellular migration and invasion (Chapter 3), I will employ
computational analyses to predict a novel mode for RHAMM secretion. In vitro studies will also
be performed to validate my computational predictions. As a result, I anticipate these studies to
identify a mechanism by which OC cells secrete RHAMM and which will provide insight needed
to attenuate RHAMMs’ cell surface HA receptor function.
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Methods
Computational Characterization of disorder: PONDR
All sequences used for computational analyses for RHAMM, CD44, SLC9A and CHP1 were
derived from their UniProtID number (Table 4.1). Using computational programs, regions of
RHAMMs intrinsic disorder were detected using PONDR VSL2 8, PONDR VL38, PONDR
VLXT9 and PONDR-FIT10. These four algorithms have different methods for predicting regions
of intrinsic disorder and PONDR-FIT uses a combination of six different predictors to quantitate
a score. PONDR-FIT is a meta-predictor that uses Foldindex, TopIDP, IUPred, PONDR VLXT,
PONDER VSL2, and PONDR VL3. PONDR® VLXT is capable of identifying potential
molecular interactions motifs in disordered proteins and disordered protein regions.

Secondary Structure Prediction: RaptorX
Prediction of the secondary structure for RHAMM was determined by RaptorX. This webserver
program uses components of both template-based and template-free strategies for determining
secondary structure11. With a given sequence this program can find related templates by
comparing BLAST and HHpredz sequences to predict a secondary structure model based upon
their algorithms 11.

Protein binding regions: ANCHOR analysis
ANCHOR algorithm software was used to predict prospective binding sites within RHAMMs
regions of disorder. This algorithm is based on the hypothesis that long regions of disorder
contain localized potential binding sites that are unable to form enough favorable intra-chain
interactions to fold on their own, but can possibly stabilize energy by binding with a globular
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protein12. ANCHOR works cooperatively with IUPred algorithm which is based on a total
pairwise interresidue energy estimation with the assumption that sequences will not be able to
fold due to instability in regions of disorder13.

Protein Binding Partners: STRING 9.1
Potential protein binding partners of RHAMM were predicted using the String 9.1 Platform.14
This software is a search tool for retrieving experimental and predicted interaction information
between proteins based on a confidence score.

Phosphorylation, O-link and N-link Glycosylation: PTM Analysis using NetPhos, NetOGlyc
and NetNGlyc
Sites of post-translational modification (PTM) within RHAMM were analyzed using algorithm
software that predicts sites of phosphorylation and glyocylation from a peptide sequence.
NetPhos presents an artificial neural network method that predicts the phosphorylation sites in
independent protein sequences with a sensitivity in the range from 69% to 96%15. DIPHOS uses
a web-based tool for the prediction of protein phosphorylation sites16. Together these programs
predict the number of potential serine, threonine, and tyrosine phosphorylation sites. NetOGlyc
4.017 determines the likely O-linked glycosylation sites on hydroxyl groups of a serine,
threonine, tyrosine, hydroxyline or hydroxyproline side chains and NetNGlyc 1.018 determines
the likely N-linked glycosylation sites on amide groups of an asparagine or arginine side chain
by a predetermined threshold. NetOGlyc predicts the number of likely residues containing
hydroxyl groups that have the potential for glycosylation and NetNGlyc networks could identify
86% of the glycosylated residues with an overall accuracy of 76%18.
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Cell Culture
The SV 40-Large T-Ag-transfected human OSE cell lines HIOSE-118 and HIOSE-121, BC
(MDA-MB-231, MCF-7), cervical cancer (HELA, OV2008, C13), prostate cancer (PC3),
pancreatic cancer (Panc1), colon cancer (WiDr) and OC (OVCAR5 and OV90) cell lines were
cultured in Medium 199/MCDB 105 (Sigma, St. Louis, MO) with 5% fetal bovine serum and
gentamicin. All cells were incubated at 37° C with 5% CO2.

Cytosolic Extraction by Digitonin Semipermeabilization
Protein separation protocol using Digitonin Semipermeabilization was performed as described by
Liu and Fagott, 2011
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. Cell were grown to confluency and then washed with ice-cold PBS.

After removal of PBS, 3 ml of Digitonin Solution was added to the dish which was then placed
on an orbital shaker for 10 min at 100 rpm at 4°C. The digitonin-solubilized material was
collected as the cytosolic fraction.

Western Blot
Untreated and treated cells were washed in PBS, trypsinized, pelleted, and washed 1-2 times in
cold PBS. Cells were lysed in CHAPS buffer and 30 µg of protein was separated via 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were
transferred to polyvinylidene fluoride (PVDF) membranes and blocked in 5% milk in Tween
20-Tris buffered saline. Blots were incubated in their respective primary antibodies overnight,
followed by incubation with a horseradish peroxidase- (HRP-) conjugated secondary antibody
(Fisher, Pittsburgh, PA), and developed via enhanced chemiluminescence substrate (ECL)
(Pierce/Fisher, Pittsburgh, PA). Antibodies used were monoclonal rabbit anti-CD168 RHAMM
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antibody at 1:1000 (abcam®, Cambridge, MA), mouse anti-CD44 antibody at 1:1000 (abcam®,
Cambridge, MA), and CHP1 at 1:1000 (Thermo Fisher Scientific, Waltham, MA)

Co-Immunoprecipitation (co-IP)
Whole cell lysate and cytosolic protein were mixed with A/G-agarose beads to make a working
solution of 50% protein and A/G beads of 100ul for 1 mL of solution. The solution was mixed on
a shaker for 10 minutes at 4°C. Mixture was centrifuged and supernantant was extracted. 1ug/mL
of protein incubated with the appropriate primary antibody overnight at 4°C. The following day
the solution was washed three times with PBS and subjected to western blot.

PNGase F De-Glycosylation
PNGase F assay (New England BioLabs, Ipswich, MA) was conducted as per manufacturer’s
instructions, 10 ug of cell lysate, denaturing buffer and water were combined, heated at 100 °C
for 10 minutes and chilled on ice. Glycobuffer, 10%NP-40 and water was added to make a total
reaction volume of 20 ul. One ul of PNGase F was added and mixed gently. The total reaction
was incubated for 1 hour at 37 °C and then run on a gel for analysis. Gel was stained with
coomassie blue and imaged with a BioRad Chemidoc (BioRad, Hercules CA).

Tunicamycin (TM) Treatment
One million cells were counted and seeded in a 6 well plate. Cells were serum-starved
overnight in media supplemented with 0.1% FBS. Media was changed the following day and
cells were either treated with methanol (MeOH), 2.5 µM TM or 5uM TM and then incubated
for 24 hrs at 37° C with 5% CO. After incubation, conditioned media was collected and cells
were lysed and subjected to ELISA and WB.
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Human HMMR/CD168/ RHAMM Sandwich enzyme-linked immunosorbent assay (ELISA)
RHAMM ELISA (LifeSpan BioSciences, Inc., Seattle, WA) was performed according to the
manufacturer’s recommended instructions. Prior to performing the experiments, all samples were
thawed to RT and centrifuged to remove particulate matter. Plates were read using a microplate
reader (BioTek ELx800, Winooski, VT) with a 450nm wavelength filter.

Results
RHAMM is a disordered and hydrophilic protein.
Bioinformatic analysis using disorder prediction software was used to analyze full length
RHAMM (Figure 4.1A). Intrinsic disorder analysis using multiple PONDR predictors shows
RHAMM is mostly an intrinsically disordered protein (IDP). These predictors consider a residue
disordered if the score is greater than 0.5 on the y-axis output, showing that RHAMM has
multiple intrinsically disordered regions (IDRs). RHAMM also has a mean hydropathy output
with a low mean net charge (valence). This confers a more open or unfolded conformation in
agreement of a protein structure with several regions of intrinsic disorder (Figure 4.1B).
IDPs are highly flexible and undergo constant dynamic conformational change,
increasing chances for protein-protein interaction (PPI).

Regions likely to undergo PPI in

RHAMM were predicted by the ANCHOR algorithm and found to directly correlate with the
regions of disorder (Figure 4.1C). These regions are predicted by binding sites undergoing order
to disorder transition-binding sites to globular protein binding sites13, making them susceptible
for interaction with other proteins. RaptorX computational software predicted RHAMMs’
secondary structure as more than 80% alpha- helical (Figure 4.1D). However, the software could
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not predict RHAMMs tertiary structure because highly disordered proteins that undergo constant
conformational change lack a fixed tertiary structure20. RHAMM was also analyzed using
HMMpTM computational software, which predicts topology of alpha-helical transmembrane
proteins21. This software confirmed that the localization of RHAMM is cytoplasmic based on its
amino acid (AA) sequence and lack of signal peptide sequence (Figure 4.1E).
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Figure 4.1 RHAMM is a Disordered Protein
A) PONDR (Predictor of Intrinsically Disordered Regions) detects disordered regions in
RHAMM. Regions shown above the 0.5 threshold are disordered and confers protein flexibility
and plasticity. B) Prediction of RHAMMs hydropathy mean net charge based off of its AA
sequence. C) RaptorX property prediction of RHAMMs secondary structure based off of AA
sequence. D) ANCHOR prediction of protein-protein interaction (PPI) binding regions
undergoing order to disorder transition-binding sites to globular protein binding site. E)
HMMpTM prediction of RHAMMs cellular localization.
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In silico identification of possible protein chaperones for RHAMM
Disordered proteins are well documented for their plasticity and promiscuity when
interacting with other proteins22. RHAMMs’ multiple regions of intrinsic disorder confer a high
propensity for PPIs. Therefore I sought to identify proteins which might serve as RHAMM
chaperones for extracellular transport of RHAMM. STRING computational software utilizes a
database of reported experimental PPI interactions based off of a publication database14. An
interactome of proteins was created and illustrated proteins that directly interact with RHAMM
(Figure 4.2A). Proteins that were likely candidates for cell surface exportation were selected for
further in silico analysis based on their canonical function. As a result, CD44, SLCA9A and
CHP1 were subjected to bioinformatic analyses of predicted intrinsic disorder, hydrophobicity,
protein binding regions and cellular localization (Figure 4.2B-E). Protein characteristics utilized
for further experimentation were based on canonical cellular function, regions of intrinsic
disorder, low mean scaled hydropathy, binding regions for PPI and cellular localization (Figure
4.2A-E). CD44 and CHP1 were the most ideal candidates because they are mostly disordered
which increases the chance of PPIs and they have low mean scale hydropathy numbers
conferring an open configuration. Predicted localization of CD44 at the cell surface would
potentiate the possibility of intracellular interaction prior to the plasma membrane for export. In
contrast, CHP1 is a cytoplasmic protein that could bind to RHAMM and mediate RHAMMs’
transport for exocytic membrane trafficking. SLC9A was also considered for RHAMM transport,
however, it is the least likely candidate due to the fact that it is mostly ordered, has a high mean
scale hydropathy and contains PPI binding sites predominantly at the c-terminus, easily hidden
by its closed configuration.
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CD44- Transmembrane protein receptor for HA
and other ligands, such as osteopontin, collagens,
and matrix metalloproteinases. Can form a
trimeric complex with HA and RHAMM on the
cell surface.
Solute carrier protein 9A (SLC9A)- linker
between integral membrane and cytoskeletal
proteins
Calcium binding protein (CHP1) - regulates
vesicular trafficking (exocytic membrane traffic)
and mediates the association between
microtubules and membrane-bound organelles of
ER and Golgi.

A

Figure 4.2 In silico identification of potential protein binding partners for RHAMM.
(Continued on Next Page)
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Figure 4.2 In silico identification of potential protein binding partners for RHAMM.
(Continued on Next Page)

73

D

E

Figure 4.2 In silico identification of potential protein binding partners for RHAMM.
A) STRING analysis of RHAMMs potential binding partners utilizing a protein database of
known interactions. B) PONDR predicted regions of protein disorder in CD44, SLC9A and
CHP1 using a threshold of 0.5. C) Prediction of CD44, SLC9A and CHP1 hydrophobicity
detected by their mean net charge based off each AA sequence. D) ANCHOR prediction of PPI
regions of CD44, SLC9A and CHP1 undergoing order to disorder transition-binding sites to
globular protein binding site. E) HMMpTM prediction of CD44, SLC9A and CHP1 cellular
localization based off AA sequence.
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CHP1 binds to RHAMM in the cytosol
To determine if RHAMM transport and secretion to the cell surface occurs by protein
chaperones, cytosolic protein was extracted by cell fractionation in HIOSE, cervical cancer and
OC cells. Even though RHAMM and CD44 have a well-documented interaction on the surface
of malignant cells and form a trimeric complex for HA interaction23,24,25, I was unable to detect
CD44 in the cytosolic protein extract (Figure 4.3A). Likewise, I was unable to detect significant
amounts of SLC9A within cellular extracts (Figure 4.3B). Therefore, I eliminated both CD44 and
SLC9A as a possible RHAMM chaperones. Without either CD44 or SCL9A in the cytosol, there
is little reason to believe that either would form an intracellular complex with RHAMM before
exportation to the membrane.
Subsequently, I performed a co-IP on cytosolic protein of OC cells (OVCAR5 and
OV90) and found that RHAMM and CHP1 interact within the cytosol (Figure 4.3C). IgG protein
was used as a control for non-specific binding. Consequently, a CHP1:RHAMM protein complex
may chaperone RHAMM secretion.
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Figure 4.3 CHP1 Binds to RHAMM in the Cytosol
WB of normal (HIOSE-118, HIOSE 121), cervical cancer (OV2008, C13) and OC (OVCAR5,
OV90) whole cell lysate and cytosolic protein. GAPDH was used as a loading control (A,B).
Primary antibodies anti-RHAMM, anti-CD44 (A) and anti- SLC9A (B) were used. Digitonin
semi-permeabilization was performed to separate cytosolic (C) protein from whole cell lysates
(W). C) Co-IP was performed on whole cell proteins and cytosolic proteins from OVCAR5 and
OV90 cells which were incubated with either anti-RHAMM or anti-CHP1 overnight with protein
A/G-PLUS agarose beads, followed by WB. IgG was used as a control for non-specific binding.
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RHAMM is not dependent on CHP1 for protein export
CHP1 inhibition was performed using siRNA CHP1 silencer followed by WB. I found
that inhibition of CHP1 expression slightly decreased RHAMM levels in OVCAR5 and OV90
cells. (Figure 4.4A) Conversely, cells were also transfected with siRHAMM silencing RNA and
WB showed that CHP1 levels did not significantly change with loss of RHAMM. This indicated
that their protein levels were not dependent on each other even though they interact within the
cell. Importantly, there was no significant difference in secreted RHAMM levels after CHP1
inhibition (Figure 4.4B) suggesting that even though RHAMM can bind to CHP1, CHP1 is not
essential for RHAMM secretion.
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Figure 4.4 RHAMM is not dependent on CHP1 for Protein Export
(A) WB of OVCAR5 and OV90 cells treated with siCHP1, siRHAMM, scrRNA or untreated (as
control) incubated with either anti-RHAMM or anti-CHP1. β- actin was used as a loading
control. (B) ELISA performed on CCM from 1x106 cells treated with siCHP1, siRHAMM,
scrRNA or untreated. ELISA results are expressed as a mean pg/mL RHAMM ± SE and
represented as a histogram where p≤0.05 was considered statistically significant.
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RHAMM has a high propensity for PTM
Further computational analysis of RHAMM was needed to delineate RHAMMs’
mechanism for secretion. Proper protein folding and function as well as protein interactions
through IDPs are typically dictated by PTM26. Potential phosphorylation, O and N-linked
glycosylation sites within RHAMM were determined using prediction.software NetPhos 2.015,
NetOGlyc 4.018 and NetNGlyc 1.018. These programs determine the propensity for
phosphorylation, O- and N- linked glycosylation of each residue of RHAMM based on the AA
sequence of RHAMM (Figure 4.5A-C). Each program designates a threshold to be passed for
significantly high level of confidence for each residue output. As shown, RHAMM has many
potential sites for phosphorylation and O- and N- linked glycosylation.
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Figure 4.5 RHAMM has a high potential to undergo PTM.
Predictions for RHAMMs potential sites of (A) phosphorylation (B) O-glycosylation and (C) Nglycosylation were obtained using computer software programs NetPhos, NetOGlyc and
NetNGyc and evaluated based on the software’s predetermined threshold for confidence,
indicated by red line.
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Inhibition of glycosylation decreases cellular RHAMM expression and secretion in OC cell
lines
To narrow down possible PTM sites, I hypothesized that N-linked glycosylation would
be the most likely mechanism driving RHAMM secretion due to its role in classical protein
secretion pathway27. To determine whether N-linked glycosylation is essential for RHAMM
secretion, OC (OVCAR5), prostate cancer (PC3), cervical cancer (HELA), BC (MDA-MB-231
and MCF7) and pancreatic cancer (Panc1) were treated with 2.5 ug/mL of Tunicamycin (TM), a
known general inhibitor of glycosylation for 24h. Cell lysates were examined by WB (Figure
4.6A) and CCM was measured by ELISA, normalized to cell number (1x106 cells) (Figure 4.6B).
WB only showed a notable reduction in RHAMM levels in OVCAR5 cell lysates suggesting that
glycosylation may not be a global mechanism for RHAMM secretion since the levels of cellular
RHAMM among the panel of remaining cell lines were not impacted by TM treatment.
Likewise, while both MDA-MB-231 and OVCAR5 cells showed reduced secretion of RHAMM
following TM treatment, only OVCAR5 cells demonstrated reduction of both cellular and
secreted RHAMM following TM treatment.
To verify a role of glycosylation for RHAMM secretion in OC, I examined whether
cellular and secreted RHAMM levels are also inhibited following TM treatment in another OC
cell line, OV90. OVCAR5 and OV90 cells were treated for 24h with 0 ug/ml, 2.5 ug/mL and
5ug/mL TM. Cell lysates were collected and subjected to both WB and ELISA (Figure 4.6C,D).
WB showed a significant decrease in RHAMM protein with both 2.5ug/mL and 5ug/mL
treatment while ELISA showed up to 3.7x and 3.29x reduction in cellular RHAMM levels
following TM treatment in OVCAR5 and OV90 cells, respectively. Corresponding CCM was
also collected, normalized to cell number and measured for RHAMM levels by ELISA (Figure
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4.6E). I found that TM reduced secreted amounts of RHAMM by up to 6.23x and 2.65x in
OVCAR5 and OV90 cells, respectively suggesting that, by maintaining protein stability and
proper protein folding to prevent lysosome or proteasome degradation28,29, glycosylation

OVCAR5 TM*

OVCAR5 Control

PC3 TM*

PC3 Control

PANC1 TM*

PANC1 Control

MCF7 TM*

MCF7 Control

MDA-MB-231 TM*

HELA TM*

HELA Control

A

MDA-MB-231 Control

mediates RHAMM secretion in OC cells.

HELA: Cervical Cancer
MDA-MB-231: Breast Carcinoma
MCF7: Breast Carcinoma
PANC1: Pancreatic Carcinoma
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Figure 4.6 TM treatment abrogates RHAMM expression and secretion in OC. (Contined
on Next Page)
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Figure 4.6 TM treatment abrogates RHAMM expression and secretion in OC.
(A) OC (OVCAR5), prostate cancer (PC3), cervical cancer (HELA), BC (MDA-MB-231 and
MCF7) and pancreatic cancer (Panc1) cells were treated with TM for 24h using vehicle control
(MeOH) and 2.5 ug/mL and subjected to WB (B). CCM corresponding to (A) was normalized to
cell number (1x106 cells) and subjected to RHAMM ELISA. (C) OC cells (OVCAR5 and OV90)
were treated with TM for 24h using vehicle control (MeOH), 2.5 ug/mL, or 5ug/mL TM.
Following TM treatment, OC cell lysates were subjected to WB (C) and ELISA (D) for
RHAMM. CCM corresponding to (C) was normalized from 1x106 cells and measured by
RHAMM ELISA (E). ELISA results are expressed as a mean pg/mL RHAMM ± SE and
represented by histogram where p≤0.05 * and p≤0.0001** were considered statistically
significant.

RHAMM is N-glycosylated
To better characterize RHAMM glycosylation, I sought to determine if RHAMM is specifically
N-glycosylated by treating OC cells with Rapid PNGase F. PNGase F enzymatically removes Nlinked oligosaccharides from glycoproteins which can be visualized on SDS-PAGE stained with
Coomassie as cleavage products of a target protein. Cellular lysates collected from OVCAR5 and
OV90 cells following digestion with PNGase F were subjected to SDS-PAGE (Figure 4.7).
Compared to untreated controls, I was able to detect cleaved protein bands of RHAMM smaller
than their parental protein (<85kDa) indicating that, at least a portion, of cellular RHAMM is Nglycosylated in OC cells.
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Figure 4.7 RHAMM is N-Linked Glycosylated
Triplicate cultures OC cells (OVCAR5 and OV90) were treated with PNGase F, electrophoresed
by SDS-PAGE and coomassie stained. Images were taken with a ChemiDoc.

Conclusion
Cytoplasmic proteins that have dualistic function on the extracellular surface are
commonly associated with oncogenic properties such that they are often activated/overexpressed
during malignant transformation30. Since I am interested in the role of extracellular RHAMM to
promote OC cell migration and invasion and that RHAMM lacks a conventional export peptide
sequence or reported use of alternate secretory pathway, it was important to begin to study
potential and unconventional export pathways for RHAMM secretion in OC. This prompted me
to perform computation analyses of RHAMM in order to better understand and characterize its
biochemical structure.
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Computational analyses indicated that RHAMM is a very disordered protein, it is
comprised mostly alpha-helical domains and it has a high propensity for PPI and PTMs.
Potential protein binding partners of RHAMM were identified as CD44, SLC9A and CHP1.
Since these proteins have the ability to either transport to the plasma membrane or are known
trafficking proteins, there were selected as candidate chaperones for RHAMM secretion.
However, I was only able to demonstrate interaction between RHAMM and CHP1 in vitro by
WB and immunoprecipitation assays. Unfortunately, abrogation of CHP1 failed to reduce
cellular expression of RHAMM or its secretion suggesting that a RHAMM/CHP1 interaction
complex is not responsible or necessary for RHAMM secretion by OC cells.
Since PTMs largely contribute to the functional complexity and diversity of the
proteome, I subsequently sought to determine whether PTMs could be responsible for RHAMM
secretion by OC cells. My computational studies identified several phosphorylation and N-/Oglycosylation sites in RHAMM. Glycosylation is a post-translational protein modification
resulting in the addition of oligosaccharides on specific AAs. Since protein glycosylation is often
crucial for protein function as it enables proteins to participate in diverse and essential biological
functions, it is not surprising that alterations in protein glycosylation can facilitate development
of neoplastic disease31. In vitro abrogation of global RHAMM glycosylation with TM resulted
in significant reduction of both cellular RHAMM and secreted RHAMM indicating that a
considerable proportion of intracellular and extracellular RHAMM is glycosylated in OC cells.
N-glycosylated proteins frequently function as cell surface receptors and/or membrane
proteins mediating cell-cell interactions32. N-glycosylation (GlcNAc-β-Asn) involves a step-wise
process by which preassembled dichol-linked triglucosylate polymannose oligosaccharides are
added to asparagine residues in the endoplasmic reticulum (ER)33. Classical protein transport to
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the ER for GlcNAc-β-Asn requires the presence of a specific consensus sequence, which has not
been experimentally shown in RHAMM. However, using predictive computational software
(NetNGlyc 1.034), I found that RHAMM was predicted to have multiple sites for potential
GlcNAc-β-Asn. Using a PNGase F assay, which cleaves N-glycans and high mannose from
glycoproteins, thereby preventing protein N-glycosylation, I was further able to show that a
substantial amount of RHAMM is N-glycosylated in OC in keeping with a cell surface function
of RHAMM.
In contrast, O-glycosylation (O-GalNAc) is the addition of an oligosaccharide onto the
hydroxyl group of a serine or threonine residues. O-GalNAc is carried out by GlcNc-transferase
and was identified as the first glycopeptide forming enzyme to act outside of the classically
defined secretory pathway35. Since RHAMM contains a myriad of sites for potential Oglycosylation predicted by computational software (NetOGlyc 4.036), it might be useful in future
studies to validate O-GalNAc of RHAMM in OC cells as well as to determine whether this PTM
plays a role in RHAMM secretion.
Taken together, my data suggest that glycosylation of RHAMM may promote
extracellular RHAMM function and oncogenic potential in OC. The degree to which either O- or
N-glycosylation contributes to the etiology and progression of OC, and potentially other cancer
types, clearly warrants further study.
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Table 4.1: Protein Sequence Identifier used in Computational Analysis

Protein

UniProt Identifier

RHAMM

O75330

CD44

P16070

CHP1

Q99653

SL9A1

P19634
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Chapter 5: Urinary Levels of RHAMM are Elevated in Ovarian Cancer Patients

Background
OC is a heterogeneous disease with multiple subtypes; proven difficult to detect at an
early stage. To date, pelvic examination, ultrasound or circulating cancer antigen 125 (CA125)
serum levels are evaluated for OC detection. CA125 is elevated in about 80% of OC patients, but
fails to detect approximately 50% of stage 1 OC patients1. Serum CA125 is also frequently
upregulated in normal conditions, benign reproductive disease and other cancer types1.
Measuring CA125 levels has been reported to cause patient anxiety and, in many cases,
unnecessary surgery1. To increase specificity, multi-marker panels in combination with CA125,
such as human epididymis protein 4, are being studied, but require further validation. This
underscores the need to find new OC biomarkers which are capable of detecting disease when
treatment options are the most successful.
Since RHAMM expression appeared localized to cytoplasm, cell surface membrane and
especially at the apical cell surface in WD OC and normal FT, potentially within ovarian cystic
fluids and secreted by OC cells in vitro, I sought to determine whether RHAMM could be
secreted by OC cells and, thereby, be detected in bodily fluids. Elevated RHAMM levels in
patient urine can potentially be a prognostic marker or diagnostic marker alone or in combination
with other markers, warranting RHAMMs clinical importance.
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Methods
Patient Cohort
University of South Florida Institutional Review Board approval and patient consent was
obtained for prospective (studies #Pro00003119, #Pro00000903) and retrospective (study
#106004) collection of urine samples. Anonymized urine samples from healthy male and female
controls (N=29), patients with benign gynecological pathology (N=30), OC (N=150), lung
cancer (N=20), BC (N=20), brain cancer (N=20), head and neck (H&N) (N=19), prostate cancer
(N=22), cervical cancer (N=9), colorectal cancer (CRC) (N=21), melanoma (N=20), endometrial
cancer (N=15) as well as sarcoma (N=12) were released for research from the tissue bank at the
H. Lee Moffitt Cancer Center and the University of South Florida. All samples were centrifuged
at 3,000 x g and the supernatant was aliquoted and frozen at -20 °C before analyses were
conducted.

Western Blot (WB) Analysis
Normal and OC urine samples of equivalent volume were centrifuged at 16,000 x g using 30,000
kDa microfilters (Millipore, Bedford, MA) to concentrate the urine specimens. Concentrated
urine samples were electrophoresed via 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane. Membranes were
blocked for 1 hour at room temperature using 5% milk in tris-buffer saline with tween.
Membranes were then incubated overnight at 4°C in monoclonal rabbit anti-CD168 RHAMM
antibody (abcam®, Cambridge, MA) and then incubated for 1 hour at room temperature in goat
anti-rabbit HRP conjugated antibody (Thermo Fisher Scientific, Waltham, MA). Protein bands
were visualized using SuperSignal West Femto Substrate (Thermo Fisher Scientific, Waltham,
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MA), densitometric analysis was performed using Image Studio Lite Version 5.0 software
program.

Human HMMR/CD168/ RHAMM Sandwich enzyme-linked immunosorbent assay (ELISA)
RHAMM ELISA (LifeSpan BioSciences, Inc., Seattle, WA) was performed according to the
manufacturer’s recommended instructions for urine sample specimens. Prior to performing the
experiments, all samples were thawed to room temperature and centrifuged to remove particulate
matter. Plates were read using a microplate reader (BioTek ELx800) with a 450nm wavelength
filter.

Statistical Analysis
Samples for RHAMM ELISA were run in duplicate and concentration calculated as per
manufacturer’s protocol. Data were subjected to descriptive statistics, T-Test, Mann-Whitney U,
Wilcoxon W, Kuskal-Wallis, one-way ANOVA, Spearman’s rho, and Bonferroni post-hoc
analysis. p ≤ 0.05 was considered statistically significant.

Results
Urinary RHAMM Levels are elevated in OC Patients
By WB, urinary RHAMM protein was negligible in normal control samples (N=10), but
elevated in 6/9 (66.67%) OC samples. Lysate from the BC cell line (MCF-7) was used as a
positive control and protein bands were quantified by densitometric analysis (Figure 5.1A,B).
Further, urinary analysis of RHAMM protein levels from OC patients measured by ELISA
(N=150) averaged almost 15X higher than normal controls (N=29) (Figure 5.1C,D & Table 1).
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Urinary levels of RHAMM in normal controls averaged 8.16 pg/mL, compared to 116.66 pg/mL
in OC patient urine (p<0.0001). Additionally, ELISA measurements of urinary RHAMM from
30 women with benign gynecological diseases including ovarian cysts, uterine fibroids and
teratomas averaged 12.85 pg/mL, which is slightly higher than normal controls, but still
significantly lower than OC RHAMM levels (p<0.0001) (Figure 5.1C). Lastly, ELISA
measurements of urinary RHAMM in patients with sarcoma, melanoma, lung, breast, brain, head
and neck, prostate, cervical, CRC, and endometrial cancers were conducted (Figure 5.1D).
Although higher than benign disease and normal controls, elevated urinary RHAMM levels in
cervical and CRC cancer were not statistically significant. In contrast, minimal levels of urinary
RHAMM were found in all other remaining malignancies.
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Figure 5.1 Urinary RHAMM levels are elevated in OC patients.
Concentrated urine samples of equivalent volumes from normal controls (N=10) and patients
with OC (N=9) were screened for RHAMM by WB (A). Membranes were incubated with antiRHAMM (1:1000) overnight and visualised with enhanced chemiluminescent. BC cell lysate
(MCF-7) was used for positive control. Densitometric values were calcutlated using Image
Studio Lite Version 5.0 and represented as a histogram (B). Urinary samples were examined by
ELISA for urinary RHAMM levels in normal controls (N=29), benign gynecological disease
(N=30) and OC (N=150) (C). Urinary RHAMM levels were measured in multiple cancer types
including cervical (N=21), CRC (N=9), BC (N=20), brain (N=20), H&N (N=20), lung (N=20),
sarcoma (N=19), endometrial (N=20), bladder (N=12), and prostate (N=14) (D). ELISA results
(C,D) are expressed as a mean pg/mL RHAMM ± SE and represented as a histogram where
p≤0.05 was considered statistically significant (*).
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Urinary RHAMM Levels Decrease After OC Cytoreductive Surgery
Urinary RHAMM levels were measured by ELISA in 10 OC patients (Figure 5.2A) and
two patients with benign low malignant potential (LMP) ovarian tumors (Figure 5.2B)
immediately prior to initial cytoreductive surgery, within two weeks of cytoreductive surgery
and, where possible, at a three month post-operative follow-up. I found up to 89% reduction in
urinary RHAMM levels post-operative compared to pre-cytoreductive surgery in 7/10 OC
patients two weeks post-surgery and in 8/10 OC patients three months post-surgery. In contrast,
an increase in urinary RHAMM levels two weeks post-cytoreductive surgery was noted in 3/10
OC patients compared to pre- cytoreductive surgery urinary RHAMM levels (Figure 5.2A).
Additionally, I measured urinary RHAMM pre and post benign tumor debulking and found
minimal changes in urinary RHAMM (Figure 5.2B).

Figure 5.2 Elevated urinary RHAMM levels decrease in OC patients after tumor
debulking.
Urinary levels of RHAMM were measured by ELISA from A) 10 OC patients and B) patients
with benign LMP ovarian tumors prior to tumor removal (black bars), within two weeks of
debulking surgery (gray bars) and 3 month post debulking surgery where possible (white bars).
Results are expressed as a mean pg/mL RHAMM ± SE and represented as a histogram where
p≤0.05 was considered statistically significant (*).
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Urinary RHAMM Levels are Higher in Obese OC Patients
When comparing urinary RHAMM levels and clinical parameters (Table 1 & Figure 5.3),
urinary levels of RHAMM did not appear to be related to OC stage (Figure 5.3A), grade (B),
patient age (C), family history of BC, OC or CRC (D) or tumor mass (E,F). I found a tendency
for a higher average of urinary RHAMM levels in stage 1 and stage 3 OC patients, however, the
elevation was not significant (inset, Figure 5.3A). Interestingly, when RHAMM ELISA urinary
measurements in OC patients were aligned by body mass index (BMI), urinary RHAMM levels
in obese (OB) patients showed a propensity to be higher than overweight (OW) and normal
(NW) weight OC patients (Fig. 3G,H). While, not statistically significant, elevated urinary
RHAMM levels in obese OC patients averaged 156.2 pg/mL compared to 103.99 pg/mL and
83.55 pg/mL in overweight and normal weight OC patients, respectively.

Figure 5.3 Urinary RHAMM levels are higher in obese OC patients. (Continued on Next Page)
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Figure 5.3 Urinary RHAMM levels are higher in obese OC patients.
Urinary RHAMM levels in normal controls (N=29) and OC patients were measured by ELISA
and compared with clinical parameters including A) stage [stage 1 (N=11), stage 2 (N=2), stage
3 (N=45), stage 4 (N=6), stage 5 (N=11)], B) grade [low grade (N=23) and high grade (N=27)],
C) age (20-29 (N=2), 30-39 (N=5), 40-49 (N=9), 50-59 (N=27), 60-69 (N=31), 70-79 (N=20),
80-89 (N=11)], D) family history of OC, BC or colon cancer [NFH (N=6), FH (N=15)], E,F)
tumor size [≤6 cm (N=11), >6 cm (N=15)], and G,H) BMI [OB >30 (N=14), OW 25-29.9
(N=6), NW 18.5-24.9 (N=17)] of OC patients. Results are expressed as a mean pg/mL RHAMM
± SE and represented as a histogram where p≤0.05 was considered statistically significant.
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OC Detection Improves when Urinary RHAMM Levels are combined with Serum CA125
Levels
Urinary RHAMM levels were evaluated in 29 OC patient samples with known serum
CA125 levels (Figure 5.4). Positive prediction of OC by urinary RHAMM levels was defined by
a statistical difference compared to control with a 95% confidence interval whereas positive
prediction for OC using serum CA125 levels were defined by clinical standards2. Serum CA125
levels in 19/29 or 65.5% OC patient samples predicted positive for OC while failing to predict
OC in 10/29 or 34.5% OC samples. In contrast, 26/29 or 89.7% of the samples predicted positive
for OC by elevated urinary RHAMM levels while failing to predict 3/29 or 10.3% of the
samples. However, the combination of serum CA125 and RHAMM appeared to predict 28/29 or
96.5% of OC samples.
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RHAMM -/C
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Figure 5.4 OC prediction increases when patient urinary RHAMM levels are combined
with serum CA125 levels.
Urinary levels of RHAMM by ELISA from 29 OC patients were shown and compared to
clinically positive CA125 serum levels (>65 U/mL, green and yellow bars) or negative CA125
serum levels (<65 U/mL, blue and red bars). Urinary RHAMM was evaluated by a positive
prediction (green and blue bars) or negative prediction (yellow and red bars) for OC. Urinary
RHAMM positive prediction threshold was considered statistically significant compared to
controls with a 95% confidence interval. Results are expressed as a mean pg/mL RHAMM ± SE
and represented as a histogram.
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Conclusion
RHAMM is a non-integral, extracellular receptor protein, only loosely tethered to the cell
membrane. Originally discovered from the conditioned medium of embryonic chick heart
fibroblasts, RHAMM is either shed or secreted into the extracellular environment3. Herein, I
sought to determine if RHAMM could be detected in bodily fluids. More specifically, we sought
to determine whether elevated RHAMM levels could be detected in the urine of OC patients,
thereby serving as a potential diagnostic and/or prognostic biomarker of disease. Urinary
biomarkers are ideal for disease detection since urine collection is simple, safe, non-invasive and
cost effective. In addition, urinary proteins retain high stability and urinary filtration precludes
the presence of large proteins found in serum, such as albumin, which can confound test results.
RHAMMs’ α-helical and coiled structure confers a hydrophilic and water soluble protein
profile4 indicating RHAMM might be present in bodily fluids. Given that glomerular filtration
typically excludes high molecular weight proteins from the urine, I was surprised to detect full
length RHAMM protein at 85 kDa in OC patient urine by WB. However, my results are in
keeping with others who also reported high molecular weight proteins in urine of women at high
risk for BC including matrix metallopeptidase-2, matrix metallopeptidase-9 (MMP9) and
MMP9/neutrophil gelatinase-associated lipocalin complex (MW: 72 kDa, 92kDa and 115 kDa
respectively)5. High molecular weight proteins present in the urine are commonly associated
with renal dysfunction6. Donadio et al. (2003) reported renal impairment in both early and late
stage OC showing at least a 10% impairment of glomerular filtration rate (GFR) and creatinine
clearance in 30% of stage 1, 50% of stage 2, 56% of stage 3 and 64% of stage 4 OC patients6
suggesting that renal impairment due to disease could enable urinary transport of full-length
RHAMM. Interestingly, despite lacking a secretory signal peptide sequence, RHAMM is
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commonly secreted by cells by an alternate and, as yet, poorly understood mechanism7 so that
RHAMM may bypass glomerular filtration by an alternate transport pathway.
In this pilot study, I consistently found elevated urinary RHAMM levels in OC patients
that were significantly higher than normal healthy controls and women with benign
gynecological disease (*P<0.0001). While most patients with benign gynecological disease did
not demonstrate elevated urinary RHAMM, elevated urinary RHAMM was observed in a patient
with uterine fibroids and a patient with endometrioma. During inflammation HA levels increase
within the microenvironment which, in turn, promotes increased RHAMM secretion8 and
involvement of RHAMM in the inflammatory process9 so that inflammatory benign gynecologic
conditions, as may have been present in these two patients, could result in a transient increase in
urinary RHAMM levels. Though not statistically significant, average urinary RHAMM was also
elevated in cervical cancer and CRC. Reports of RHAMM mRNA overexpression in women
with cervical cancer

10

and intense RHAMM staining in CRC tumor budding cells associated

with a more malignant and invasive cancer phenotype11 are in agreement with my findings.
Although studies indicate elevated RHAMM in breast12, prostate13 and bladder14 tissue, my
samples did not show urinary elevations in these cancer types. However, since RHAMM
contributes to an invasive and metastatic phenotype8, it is tempting to speculate that increased
levels of RHAMM within the tumor microenvironment, and, subsequently, in the urine, may
discriminate between cancers with less than 50% 5 year survival (ovarian, cervical, colorectal)
related, in part, to metastatic spread, compared with cancer survival greater than 50% 5 year
survival such as breast, prostate, glioma and sarcoma15.
While urinary RHAMM levels were essentially unchanged in patients with benign
disease following cytoreductive surgery, reduced urinary RHAMM levels after cytoreductive
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surgery suggests that RHAMM is produced and secreted by OC cells. In contrast, increased
urinary 9 RHAMM after cytoreductive surgery could be associated with post-surgical infections
since 35.8% of patients experience symptomatic infections after cytoreductive surgery16.
When analyzing clinical parameters, average urinary RHAMM levels were independent
of age, FH and tumor mass. One might expect higher RHAMM levels in the patients with larger
tumors, however, I found no differences in average urinary RHAMM levels based on tumor
mass. This may reflect the presence of necrotic tissue often present within the central core of
tumors, thereby reducing the effective tumor volume capable of secreting RHAMM. Most
notably, I found elevated urinary RHAMM levels independent of tumor stage and grade
indicating that RHAMM could a viable diagnostic marker for detection of early stage disease,
which is imperative for successful treatment and patient survival.
Additionally, I found a trend for elevated urinary RHAMM with increasing BMI.
Multiple studies have correlated obesity with increasing risk for comorbidities such as diabetes,
hypertension and cancer17.

In OC, a meta-analysis of 121 studies provided strong

epidemiological correlation between women with a high BMI and increased risk for OC, shorter
time to disease relapse and overall survival time18.

Obesity-mediated secretion of pro-

inflammatory cytokines (IGF-1, VEGF, TNF-α and IL-6) promotes cellular dysfunction19 and
has been shown to increase the risk of multiple malignancies including high grade serous OC18.
Interestingly, the ability of obesity associated cytokines TNF-α and IL-6 to activate transcription
factor NF-κB, a common downstream effector of RHAMM20, may exacerbate tumorigenic
contributions of RHAMM. Lastly, a comparison of urinary RHAMM levels with serum CA125
levels suggested that RHAMM, in combination with CA125, can more accurately predict OC.
Going forward, then, it would be interesting to determine whether combinations of urinary levels
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of RHAMM with other biomarkers currently under clinical investigation such as mesothelin,
Bcl-2, lipoprotein A, osteopontin and the OVA1 test could likewise improve OC detection.
Taken together, I show, for the first time, elevated urinary RHAMM levels in both early
and late stage serous OC patients, minimal expression in patients with benign gynecological
disease, the potential for obesity to confound test results and improved disease detection when
urinary RHAMM levels are combined with serum CA125 measurements. This pilot study
suggests, then, that elevated urinary levels of RHAMM are associated with OC and may serve as
a novel biomarker contributing to non-invasive, economical and effective diagnostic and
prognostic applications.
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Table 5.1. Summary of patient clinical parameters
Sample

N

Normal
Benign
OC
Other Cancer
Breast
Melanoma
Brain
Head and Neck
Lung
Sarcoma
Endometrial
Bladder
Prostate
Cervical
Colorectal
STAGE
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
GRADE
Low grade
High grade
AGE (years)
20-29
30-39
40-49
50-59
60-69
70-79
80-89
Tumor Mass
0-6 cm
>6 cm
Family History
NFH
FH
BMI
N
OW
OB

29
30
150

Average Urinary
RHAMM
(pg/mL)
8.16433368
12.8451222
116.662456

20
20
20
19
20
12
14
17
21
9
21

3.038716
7.38305
7.40445
3.696184
7.797443
3.187877
6.937981
7.020548
1.647099
71.36415
80.95593

Range Lower limit

Range Upper limit

p-value

-8.50288
-1.029525763
-27.1929

54.43993895
85.95183057
1702.52388

p<0.0001
p<0.0001

-0.424456354
0.55800801
-0.459595635
-1.374710715
-10.16901388
-0.8321832
-1.31133649
-1.37833232
-2.51055025
-10.64064941
-7.359425625

23.94696898
50.54440287
46.65082733
16.36502676
113.6471452
16.26171595
94.04170598
42.53569287
19.43540151
382.2059057
321.8391349
p=0.249

11
4
45
6
11

157.635708
105.348346
162.35244
85.8344317
87.5899564

14.12994
37.508515
-10.77318
12.838485
22.47945

424.42521
143.22621
1702.52388
175.459295
239.703255

23
27

142.265278
141.993346

14.12994
-10.77318

424.42521
1702.52388

p=0.280

p= 0.832
2
5
8
27
30
20
11

98.1338875
56.173133
147.813483
91.4446452
134.730681
100.570824
93.1003286

20.80848
10.16778
-7.0938
-27.1929
-6.14796
-10.77318
8.74902

175.459295
103.32459
1702.52388
571.57434
878.01417
463.93452
226.42794

11
15

154.296986
81.4531359

27.177795
-10.77318

571.57434
262.13274

p=0.102

p=0.503
6
15

139.629013
154.676083

37.508515
-3.776025

360.736255
1702.52388
p=0.419

17
6
14

83.5546827
103.986345
156.19858

-10.77318
25.39085
12.838485
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235.54089
226.42794
424.42521
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Chapter 6: Concluding Remarks

OC is the deadliest gynecologic cancer whose molecular etiology remains poorly
understood. It is a complex and heterogeneous disease characterized by numerous potential
origins of disease from within different areas of the ovary and surrounding tissues as well as
diverse clinical presentations with multiple histologic subtypes characterized by varying
molecular profiles. Yet, despite its diversity, there is a general propensity for metastatic spread
and emergence of drug resistant disease among OCs.

Figure 6.1 Schematic representation of RHAMMs association in oncogenic signaling
pathways created with Ingenuity Pathway Analysis software.
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RHAMM has dualist functions dependent upon its cellular localization that makes it an
attractive entity to drive both metastatic spread and drug resistant disease (Figure 6.1).
Intracellularly, RHAMM is involved in microtubule spindle assembly and gene transcription
contributing to cell cycle progression. On the cell surface, loosely tethered RHAMM forms a
complex with CD44 and HA that promotes cellular migration and invasion.

Since the

contribution of RHAMM to OC progression has not been delineated, I sought to determine if
RHAMM could promote OC invasion/metastasis.
I found that RHAMM is overexpressed in clinical specimens of OC by immunohistochemistry and although both primary and metastatic OCs stain equally for RHAMM,
RHAMM staining was most intense among clinically aggressive OC histologic subtypes.
Further, using an in vitro model system, I was able to show that OC cells express and secrete
RHAMM. Abrogation of RHAMM using silencing RNA technology inhibited OC cell migration
and invasion suggesting that RHAMM may contribute, at least in part, to the metastatic
propensity of OC.
Since RHAMM lacks an export signal peptide sequence and has not been reported to
employ alternate mechanisms for extracellular secretion, I utilized computational analyses to
predict post-translational glycosylation events as a novel mode for RHAMM secretion.
Treatment with a peptide -N-glycosidase F enzyme successfully cleaved N-linked
oligosaccharides from RHAMM as seen by SDS-PAGE. Glycosylation inhibitors abrogated
RHAMM secretion by OC cells in vitro further validating my prediction for an unconventional
glycosylation-mediated mode for RHAMM secretion.
Lastly, since RHAMM is secreted by OC cells, I sought to determine whether RHAMM
could be detected in bodily fluids. In a pilot study, I found that urinary levels of RHAMM are
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elevated in OC patients as measured by ELISA. Decreased urinary RHAMM levels noted
following cytoreductive surgery support OC as the source of elevated urinary RHAMM levels.
Finally, while obesity was associated with high urinary RHAMM levels in OC patients,
combined measurements of urinary RHAMM and serum CA125 improved prediction of OC.
Though my data did not support a role for RHAMM in OC cell growth, future therapeutic
interventions targeting extracellular RHAMM could be employed for managing metastatic
spread. The use of monoclonal antibodies, such as trastuzumab, in combination with traditional
chemotherapeutics has been very successful in BC1. Trastuzumab is a monoclonal antibody
which targets the extracellular domain of HER22, thereby selectively targeting the highly
proliferative BC cells that overexpress HER2. Although, not as effective when used alone, it has
been shown to have synergistic effects when used in conjunction with cisplatin, carboplatin,
radiation and docetaxel1. Using a monoclonal antibody targeting extracellular RHAMM could
similarly reduce metastatic spread when used in combination with taxanes or platinum-based
agents in OC.
Recent advances in chemotherapeutic modalities have utilized HA as a drug target or
drug delivery carrier3. HA nanoparticle delivery systems exploit the strong binding affinity HAs
have to their receptors4. Since the HA receptor, RHAMM, is commonly overexpressed in cancer
while there is little to no RHAMM expression in normal cells, it appears reasonable to target
HA/RHAMM for selective drug delivery. HA has also been coupled to cytotoxic agents, such as
paclitaxel, and remains non-toxic until its bioconjugates are internalized3. As a result, using an
HA nanoparticle delivery system to target RHAMM could bypass the systemic cytotoxic effects
associated with traditional chemotherapy3.
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The extracellular form of RHAMM could further be targeted using an inside out
approach to prevent its cell surface localization. Glycobiology represents an active and
promising area of research for drug discovery since glycosylation patterns of proteins are
frequently altered in malignancy5. For example, N-glycosylation inhibitors are currently being
studied for their effectiveness in overcoming drug resistance in glioma by targeting
compensatory mechanisms commonly seen in malignancy6. Since I’ve shown RHAMM is likely
exported by N-glycosylation, N-glycosylation inhibitors could be useful therapies to disrupt the
extracellular distribution of RHAMM and subsequent activation of the ERK1, 2 MAPkinase
pathway6, thereby mitigating OC cell metastasis as well as emergence of drug resistant disease.
As previously mentioned, varying levels of different RHAMM isoform confers distinct
tumorigenic phenotypes. While my work was focused on the extracellular function of RHAMM
in OC, it would be interesting to more deeply explore the role of intracellular RHAMM in OC.
RHAMMs’ role in the mitotic spindle assembly and interaction with BRCA1, at both the
physical and genetic level, has been shown to have profound effects in BC suseptibility7. This
could be an area to explore in OC patients who are mutant BRCA1 or have family history of
BRCA1 mutations. Centrosome amplification is normally regulated by the BRCA-BARD1
complex, which directly interacts with RHAMM, but which results in aberrant mitotic spindle
assembly if the BRCA-BARD1/RHAMM interaction is altered8. As a result, since the BRCA1BARD1 complex is essential for proper chromosome stability and spindle formation9, mutations
in BRCA1 and/or RHAMM could interfere with spindle assembly leading to chromosomal
instability9.
Taken together, the studies described herein suggest that RHAMM contributes to OC and
that further studies are warranted to elucidate the clinical role of RHAMM in OC.
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